

Australian Prescriber

AN INDEPENDENT REVIEW

nps.org.au/australian-prescriber

June 2020
Volume 43 Number 3

CONTENTS

EDITORIAL

- Principles of ethical prescribing for self and others: hydroxychloroquine in the COVID-19 pandemic** 76

I Coombes, A Markwell, P Kubler, AM Redmond, G McGurk, JA Roberts

- COVID-19 and the quality use of medicines: evidence, risks and fads** 78

DM Roberts, A Bennett

ARTICLES

- Penicillin – getting prescribing right for children** 81

M Mostaghim, BJ McMullan, G Rowles

- Treatment of systemic lupus erythematosus** 85

KP McKeon, SH Jiang

- Lithium therapy and its interactions** 91

GS Malhi, E Bell, T Outhred, M Berk

- NEW DRUGS** 94

Abemaciclib for breast cancer
Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Ceftazidime/avibactam for specified infections
Isavuconazole for invasive fungal infections
Stiripentol for Dravet syndrome

Principles of ethical prescribing for self and others: hydroxychloroquine in the COVID-19 pandemic

Ian Coombes

Director, Department of Pharmacy¹
Associate professor, School of Pharmacy²

Alexandra Markwell

Senior staff specialist, Emergency and Trauma Centre¹

Senior lecturer, Faculty of Medicine²
Chair³

Paul Kubler

Director, Department of Rheumatology¹
Senior lecturer, Faculty of Medicine²

Andrew M Redmond

Acting director, Department of Infectious Diseases¹
Senior lecturer, Faculty of Medicine²

Gordon McGurk

Chairperson, Human Research Ethics Committee¹

Jason A Roberts

Consultant clinical pharmacist, Departments of Pharmacy and Intensive Care Medicine¹
Professor, University of Queensland Centre for Clinical Research, Faculty of Medicine and School of Pharmacy²

¹ Royal Brisbane and Women's Hospital, Brisbane

² The University of Queensland, Brisbane

³ Queensland Clinical Senate, Queensland Health, Brisbane

Keywords

COVID-19, ethics, hydroxychloroquine

Aust Prescr 2020;43:76–7

<https://doi.org/10.18773/austprescr.2020.030>

First published 22 April 2020

Prescribing medicines with putative benefit for COVID-19 disease appears very attractive to consumers, clinicians and some senior politicians.¹ However, there are no medicines with any robust evidence of clinical benefit, including the antimalarial hydroxychloroquine, the antibiotic azithromycin and the antiretroviral combination of lopinavir with ritonavir. Indeed, now is the time to investigate which drugs may improve clinical outcomes in COVID-19 by conducting well-designed clinical trials, rather than making assumptions based on preliminary data and low-quality clinical studies.² There are major trials underway in hospital wards and intensive care units, as well as in the community in the USA, Europe and Australia. Each trial will test different drugs or drug combinations, driven by locally available options.³

Hydroxychloroquine is registered in Australia for the treatment of patients with systemic lupus erythematosus, rheumatoid arthritis and malaria. It has proven benefit in these indications and is generally well tolerated by these patients. It is not yet registered for the treatment of COVID-19 in Australia and the drug toxicity profile in COVID-19 is currently unknown. It may prove to be dependent on both the patient population, the dose administered and the concomitant drug therapies. Without knowing the effective drug concentrations, non-optimised dosing may expose patients to serious adverse effects, such as seizures and cardiac toxicity.⁴

Some clinicians and consumers may believe that hydroxychloroquine should be available on compassionate grounds for patients with COVID-19 who are not eligible or do not give their consent for recruitment into a clinical trial.⁵ Hydroxychloroquine should only be prescribed after the patient or their carer has been made aware of the drug's potential toxicities and its lack of proven efficacy in COVID-19, and consent has been given.

There are also proposals from some clinicians to take hydroxychloroquine prophylactically following high-risk exposure such as intubating or extubating infected patients. Although pre-exposure and

post-exposure prophylaxis trials have already commenced, or will do so imminently, the use of hydroxychloroquine should be conserved for proven therapeutic indications or as part of a randomised controlled trial.⁶

Due to inappropriate prescribing and dispensing, hydroxychloroquine is now in short supply in Australia and globally. This has caused serious challenges for patients receiving ongoing treatment for chronic diseases such as lupus for which there often is not an effective alternative,⁷ and even temporary withdrawal can lead to serious harm.⁸ While patients with rheumatoid arthritis could be managed with alternative disease-modifying drugs, this is inconvenient as they need to have additional specialist consultations. It is encouraging that pharmacy and medical professional organisations are also conveying similar messages regarding the limited evidence of drug efficacy and safety in COVID-19, as well as the importance of ongoing access to essential treatments for chronic diseases.^{9,10}

There may be a temptation to self-prescribe hydroxychloroquine or prescribe it for family and friends. Each state and territory has specific legislation that regulates this type of prescribing. The Good Medical Practice guide from the Medical Board of Australia cautions against prescribing for self, family, friends or coworkers. The Guide recommends 'seeking independent, objective advice when you need medical care, and being aware of the risks of self-diagnosis and self-treatment'.¹¹ In other words, all health professionals should have their own doctor. The guide also advises doctors against providing medical care to anyone with whom they have a close personal relationship because of the lack of objectivity, possible discontinuity of care and the risks to the doctor and patient.

Some may argue that in a pandemic, prescribing outside of the guidelines is justified. However, from a medico-ethical and possibly legal perspective, the answer should be 'no' when considering a request to prescribe for a family member or close friend.¹² If you

are asked for such a prescription, it is important to ask yourself:

- Have I made an objective and independent decision to prescribe the most suitable medicine for the condition in this situation?
- Am I able to provide appropriate care for my family or friend?
- Am I following my usual practice and scope in prescribing in this situation?
- Would my peers agree that this was consistent with good practice?
- Would our relationship survive, and could I be considered as having not executed my duty of care or even of being negligent if an adverse drug event occurred?

Prescribing medicines for COVID-19 lacks evidence, risks toxicity and may prevent others accessing essential treatments for chronic diseases. Using hydroxychloroquine or other unproven medicines as a possible standard of care for the treatment or prevention of COVID-19 raises ethical issues of resource allocation as well as beneficence. Drugs must be reserved for approved indications for

which they are a first-line treatment. Conversely, while many are hopeful that hydroxychloroquine may prove to be the panacea that will help us lessen the effect of COVID-19 in the population, its use outside of a clinical trial should be avoided until more evidence is available.¹³ ◀

Ian Coombes is the Director of the Royal Brisbane and Women's Hospital pharmacy department, which has an interim licence to support pharmacy activities associated with COVID-19 clinical trials, including the Australasian COVID-19 Trial (ASCOT) involving hydroxychloroquine.

Andrew Redmond is an associate investigator and Jason Roberts is an investigator on the ASCOT study. Funding for this study has come from donors and the authors do not receive any financial advantage for their participation.

Paul Kubler is principal site investigator for Abbvie for two phase III trials on drugs for psoriatic arthritis and systemic lupus erythematosus. He does not receive any financial benefit for participation. Funding goes to a public hospital research trust fund.

REFERENCES

1. Thomas K, Grady D. Trump's embrace of unproven drugs to treat coronavirus defies science. *New York Times* 2020 Mar 20. <https://www.nytimes.com/2020/03/20/health/coronavirus-chloroquine-trump.html> [cited 2020 Mar 20]
2. Kim AHJ, Sparks JA, Liew JW, Putman MS, Berenbaum F, Duarte-García A, et al; COVID-19 Global Rheumatology Alliance. A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19. *Ann Intern Med* 2020 Mar 30. [Epub ahead of print]. <https://doi.org/10.7326/M20-1223>
3. Adaptive COVID-19 Treatment Trial. *ClinicalTrials.gov* identifier: NCT04280705. First posted 2020 Feb 21. <https://clinicaltrials.gov/ct2/show/NCT04280705?term=remdesivir&cond=covid-19&draw=2&rank=5> [cited 2020 Mar 20]
4. Ruiz-Irastorza G, Ramos-Casala M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. *Ann Rheum Dis* 2010;69:20-8. <https://doi.org/10.1136/ard.2008.101766>
5. The Council of Australian Therapeutic Advisory Groups. Rethinking medicines decision-making in Australian hospitals: guiding principles for the quality use of off-label medicines. Sydney: CATAG; 2013. <http://www.catag.org.au/rethinking-medicines-decision-making-2/> [cited 2020 Apr 20]
6. Kalil AC. Treating COVID-19-off-label drug use, compassionate use and randomized clinical trials during pandemics. *JAMA* 2020 Mar 24. [Epub ahead of print]. <https://doi.org/10.1001/jama.2020.4742>
7. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis* 2019;78:736-45. <https://doi.org/10.1136/annrheumdis-2019-215089>
8. Canadian Hydroxychloroquine Study Group. A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. *N Engl J Med* 1991;324:150-4. <https://doi.org/10.1056/NEJM199101173240303>
9. Freeman C. Prescribing hydroxychloroquine for COVID-19 [open letter to prescribers]. Canberra: Pharmaceutical Society of Australia; 2020 Mar 21. <https://www.psa.org.au/prescribing-hydroxychloroquine-for-covid-19> [cited 2020 Apr 20]
10. Hendrie D. Many use malaria drug as coronavirus protection – but evidence lacking. *News GP* 2020 Mar 23. <https://www1.racgp.org.au/newsgp/clinical/many-flock-to-malaria-drug-for-coronavirus-protect> [cited 2020 Apr 20]
11. Medical Board of Australia. Good medical practice: a code of conduct for doctors in Australia. 2014 Mar 17. <https://www.medicalboard.gov.au/Codes-Guidelines-Policies/Code-of-conduct.aspx> [cited 2020 Apr 21]
12. Bird S. The pitfalls of prescribing for family and friends. *Aust Presc* 2016;39:11-3. <https://doi.org/10.18773/austprescr.2016.002>
13. Australian Government Department of Health. Australian Health Protection Principal Committee (AHPPC) coronavirus (COVID-19) statements on 7 April 2020. Advice on off-label medicines for treatment and prophylaxis of COVID-19. <https://www.health.gov.au/news/australian-health-protection-principal-committee-ahppc-coronavirus-covid-19-statements-on-7-april-2020#advice-on-offlabel-medicines-for-treatment-and-prophylaxis-of-covid19> [cited 2020 Apr 20]

COVID-19 and the quality use of medicines: evidence, risks and fads

Darren M Roberts

Clinical pharmacologist and Nephrologist, Departments of Clinical Pharmacology and Toxicology, and Renal Medicine and Transplantation, St Vincent's Hospital, Sydney

Conjoint associate professor, St Vincent's Clinical School, University of New South Wales, Sydney

Alexandra Bennett

Executive officer, NSW Therapeutic Advisory Group, Sydney

Keywords

coronavirus, COVID-19, pandemic

Aust Prescr 2020;43:78–80

<https://doi.org/10.18773/austprescr.2020.031>

First published 8 May 2020

Related article:

[Principles of ethical prescribing for self and others: hydroxychloroquine in the COVID-19 pandemic](#)

The COVID-19 pandemic is rapidly evolving and determining the appropriate response is complex. The severity of COVID-19 and the limited evidence for any treatment have added to the complexity of clinical decision making and prescribing. A vaccine is not yet available, but decisions about treatment are needed now.

Fear in the community has resulted in people trying unproven remedies. These fads include consuming bleach,¹ and gargling warm salt water or vinegar.² Each fad has varying toxicity and none is of likely benefit. Consuming chloroquine from an aquarium product³ and drinking methanol have been fatal.⁴ High-dose vitamin C has been discouraged as a treatment for COVID-19,⁵ but reports that it is being prescribed to,⁶ and studied in,⁷ patients with COVID-19 could confuse the public about its place in therapy. These examples highlight the need for balanced discussions of the harms and benefits of each proposed treatment.

Australian healthcare workers have the opportunity to learn from colleagues overseas with advice being received daily. There are many anecdotes about treatment, usually conveying a brief and narrow perspective. Each can consciously and subconsciously influence our clinical decisions.

Information about the purported effects of drugs in COVID-19 is rapidly changing. Most reports focus on what is new, rather than summarising what has been learnt to date. It is easy to miss when a treatment claim becomes discredited or raises new safety concerns.

Currently, supportive care is the mainstay of treatment for COVID-19. Suggested drug treatments have been based mostly on in vitro studies or biomarkers from observational studies. At best, preliminary data from these studies should be considered hypothesis generating and prompt more research, rather than guiding clinical management. Many clinicians are not experts in research methods, so we may not appreciate the limitations of the results based on the shortcomings of the methods used in some of these studies.

Over 300 trials including more than 50 drug or biological treatments for COVID-19 have been registered.⁸ These will generate both hope and uncertainty. Currently the main approaches include inhibiting viral replication with chloroquine, hydroxychloroquine or antiviral drugs,⁹ immune modulation by corticosteroids, tocilizumab or stem cells, and administration of convalescent sera.

Some studies that have been popularised by the media have been uploaded to online preprint servers without the rigour of peer review. This may not be apparent from an abstract or media report so a high level of scepticism is required.

A global survey of physicians in early April 2020 found that hydroxychloroquine and azithromycin were prescribed or seen to be prescribed by nearly 50% of respondents. However, only 38% perceived efficacy in COVID-19.¹⁰ Some healthcare workers have prescribed hydroxychloroquine for themselves and their families. This represents extrapolation of the very low-quality evidence for treatment¹¹ to experimental use for prophylaxis.¹² The decision may have been their own, but it has been rumoured that some doctors were advised by their employer to self-prescribe hydroxychloroquine due to their increased risk of being infected by patients with COVID-19. This highlights the ethical questions about prescribing experimental treatments.¹³ It is important to distinguish off-label from experimental prescribing.

Given the rate that the pandemic is evolving, the processes required to start a clinical trial may appear prolonged. However, these processes are necessary to develop a protocol, allocate resources and ensure patients are monitored to avoid treatment-related deaths. An experimental treatment should only be prescribed after informed consent is obtained.

The doses of some drugs being prescribed for COVID-19 are high compared to those used for their approved indications. Clearly, the greater the dose the greater risk of harm, and this is likely to be compounded in older patients with multiple comorbidities or those with viral myocarditis.

Some studies have used combinations of drugs which makes it difficult to assess their individual efficacy and toxicity. The combination of hydroxychloroquine and azithromycin is associated with cardiotoxicity, including a newly prolonged QTc interval of over 500 ms in 10–20% of participants.^{14,15} A preprint publication of a retrospective study reported higher mortality in patients receiving hydroxychloroquine than those who did not.¹⁶ Cardiotoxicity including ventricular tachycardia and death with higher doses of chloroquine prompted the early cessation of a Brazilian study.¹⁷ Preventable drug-induced toxicity due to overdosage may have occurred in other

pandemics, including aspirin for influenza in 1918–19¹⁸ and ribavirin for severe acute respiratory syndrome in 2003.¹⁹

In March 2020 there was much discussion that renin–angiotensin system inhibitors may increase the severity of COVID-19.^{20–22} Much of this concern then subsided and it was recommended for patients taking these drugs to continue them.^{20,22} The harm from stopping these drugs in patients with heart failure or other high-risk cardiovascular conditions is probably far greater than the unproven risk of severe COVID-19.^{23,24} Subsequent studies confirmed that there was no increased risk from COVID-19 with renin–angiotensin system inhibitors,^{25–28} confirming the earlier advice. There have also been concerns about non-steroidal anti-inflammatory drugs (NSAIDs) notably ibuprofen.²¹ The current position is that NSAIDs can be used when indicated, but paracetamol is likely to be an acceptable alternative.^{29–32}

Another risk from the increased prescribing of unproven drugs is that it creates a shortage of these drugs for patients who rely on them. For example, there has been a shortage of hydroxychloroquine for systemic lupus erythematosus, and reports of possible ivermectin efficacy in COVID-19 led to shortages within days. The shortages also impact on the supply

of medicines for clinical trials. Regulators, funders and policymakers have needed to enforce or introduce regulations to prevent inappropriate prescribing and stockpiling. The Therapeutic Goods Administration and Pharmaceutical Benefits Scheme have now restricted who can prescribe hydroxychloroquine.^{33,34}

COVID-19 is presenting a number of challenges. We should not compound the crisis by inappropriate prescribing based on inadequate evidence, which increases the risk of harm and causes drug shortages. At present all prescribing for COVID-19 is experimental. Healthcare professionals must constantly analyse the literature and stay up to date using trusted resources. We need to explain clearly the challenge of balancing harm and benefit to our patients, friends and family. The COVID-19 pandemic is an opportunity to improve the health literacy of the public and to emphasise the principles of the quality use of medicines to ensure drugs are used safely and effectively. ◀

Darren Roberts is the Chair of the Editorial Executive Committee of Australian Prescriber.

Darren Roberts acknowledges support of the Clinician 'Buy-Out' Program, St Vincent's Centre for Applied Medical Research.

REFERENCES

- Spencer SH. Fake coronavirus cures, part 1: MMS is industrial bleach. FactCheck.org 2020 Feb 11. <https://www.factcheck.org/2020/02/fake-coronavirus-cures-part-1-mms-is-industrial-bleach> [cited 2020 May 4]
- False claim: gargling with warm water and salt or vinegar will kill the coronavirus. Reuters Fact Check 2020 Mar 18. <https://www.reuters.com/article/uk-factcheck-coronavirus-salt-vinegar-idUSKBN2142MW> [cited 2020 May 4]
- Beasley D. Arizona man dies after taking chloroquine for coronavirus. Reuters 2020 Mar 24. <https://www.reuters.com/article/us-health-coronavirus-usa-chloroquine-idUSKBN21A3Y2> [cited 2020 May 4]
- Trew B. Coronavirus: hundreds dead in Iran from drinking methanol amid fake reports it cures disease. Independent 2020 Mar 27. <https://www.independent.co.uk/news/world/middle-east/iran-coronavirus-methanol-drink-cure-deaths-fake-a9429956.html> [cited 2020 May 4]
- Spencer SH. Fake coronavirus cures, part 3: vitamin C isn't a shield. FactCheck.org 2020 Feb 12. <https://www.factcheck.org/2020/02/fake-coronavirus-cures-part-3-vitamin-c-isnt-a-shield> [cited 2020 May 4]
- Mongelli L, Golding B. New York hospitals treating coronavirus patients with vitamin C. New York Post Metro 2020 Mar 24 <https://nypost.com/2020/03/24/new-york-hospitals-treating-coronavirus-patients-with-vitamin-c> [cited 2020 May 4]
- Vitamin C infusion for the treatment of severe 2019-nCoV infected pneumonia. ClinicalTrials.gov. NCT04264533 <https://clinicaltrials.gov/ct2/show/NCT04264533> [cited 2020 May 4]
- Burk-Rafel J. Updated summary of all current #COVID19 clinical trials. Incredibly, 102 trials were posted last week! [Twitter post]. 2020 Apr 6. <https://twitter.com/jbrafel/status/1247058257341972482> [cited 2020 May 4]
- Belhadi D, Peiffer-Smadja N, Lescure F-X, Yazdanpanah Y, Mentré F, Laouénan C. A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19. MedRxiv [preprint] 2020 Mar 27. <https://www.medrxiv.org/content/10.1101/2020.03.18.20038190v2>
- Sermo reports hydroxychloroquine usage expands globally, plasma is perceived as more effective than hydroxychloroquine, remdesivir efficacy perceptions on the rise: data from week two of largest ongoing international market research study on COVID-19. Businesswire 2020 Apr 8. <https://www.businesswire.com/news/home/20200408005387/en/Sermo-Reports-Hydroxychloroquine-Usage-Expands-Globally-Plasma> [cited 2020 May 4]
- Hydroxychloroquine and COVID-19. Updated 2020 Apr 29. Sydney: NPS MedicineWise; 2020. <https://www.nps.org.au/hcq-and-covid-19> [cited 2020 May 4]
- Mannix L. Dentists banned from prescribing potential COVID-19 drug to self, family. Sydney Morning Herald 2020 Mar 24. <https://www.smh.com.au/national/dentists-banned-from-prescribing-potential-covid-19-drug-to-self-family-20200324-p54db2.html> [cited 2020 May 4]
- Coombes I, Markwell A, Kubler P, Redmond AM, McGurk G, Roberts JA. Principles of ethical prescribing for self and others: hydroxychloroquine in the COVID-19 pandemic. Aust Prescr 2020 Apr 22 [Epub ahead of print]. <https://doi.org/10.18773/austprescr.2020.030>
- Chorin E, Dai M, Shulman E, Wadhvani L, Bar-Cohen R, Barbhaiya C, et al. The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin [letter]. Nat Med 2020 Apr 24 [Epub ahead of print] <https://www.nature.com/articles/s41591-020-0888-2>
- Mercuro NJ, Yen CF, Shim DJ. Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020 May 1 [Epub ahead of print]. <https://jamanetwork.com/journals/jamacardiology/fullarticle/2765631>
- Magagnoli J, Narendran S, Pereira F, Cummings T, Hardin JW, Sutton SS, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. MedRxiv [preprint] 2020 Apr 23. <https://www.medrxiv.org/content/10.1101/2020.04.16.20065920v2>

17. Borba MG, Val FF, Sampaio VS, Alexandre MA, Melo GC, Brito M, et al; CloroCovid-19 Team. Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. *JAMA Netw Open* 2020;3:e208857. <https://doi.org/10.1001/jamanetworkopen.2020.8857>
18. Starko KM. Salicylates and pandemic influenza mortality, 1918–1919 pharmacology, pathology, and historic evidence. *Clin Infect Dis* 2009;49:1405-10. <https://doi.org/10.1086/606060>
19. Muller MP, Dresser L, Raboud J, McGeer A, Rea E, Richardson SE, et al; Canadian SARS Research Network. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. *Pharmacotherapy* 2007;27:494-503. <https://dx.doi.org/10.1592%2Fphco.27.4.494>
20. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. *N Engl J Med* 2020;282:1653-9. <https://doi.org/10.1056/nejmsr2005760>
21. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? *Lancet Respir Med* 2020;8:e21. [https://doi.org/10.1016/s2213-2600\(20\)30116-8](https://doi.org/10.1016/s2213-2600(20)30116-8)
22. ACE2 and hypertension. #NephJC 2020 Mar 14. <http://www.nephjc.com/news/covidace2> [cited 2020 May 4]
23. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). *Clin Infect Dis* 2020 Mar 9; ciaa237 [Epub ahead of print]. <https://doi.org/10.1093/cid/ciaa237>
24. Zaman S, MacIsaac AI, Jennings GLR, Schlaich M, Inglis SC, Arnold R, et al. Cardiovascular disease and COVID-19: Australian/New Zealand consensus statement. *Med J Aust* 2020 April 3. <https://www.mja.com.au/journal/2020/cardiovascular-disease-and-covid-19-australiannew-zealand-consensus-statement> [cited 2020 May 4]
25. Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. *JAMA Cardiol* 2020 Apr 23;e201624 [Epub ahead of print]. <https://doi.org/10.1001/jamacardio.2020.1624>
26. Mehra MR, Desai SS, Kuy SR, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. *New Engl J Med* 2020 May 1 [Epub ahead of print]. <https://doi.org/10.1056/NEJMoa2007621>
27. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-angiotensin-aldosterone system blockers and the risk of Covid-19. *New Engl J Med* 2020 May 1 [Epub ahead of print]. <https://doi.org/10.1056/NEJMoa2006923>
28. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. *N Engl J Med* 2020 May 1 [Epub ahead of print]. <https://doi.org/10.1056/NEJMoa2008975>
29. Ibuprofen and COVID-19. *British Pharmacological Society News* 2020 Mar 18. <https://www.bps.ac.uk/news-events/news/articles/2020/ibuprofen-and-covid-19> [cited 2020 May 4]
30. World Health Organization. Could #ibuprofen worsen disease for people with #COVID19 [Twitter post]. 2020 Mar 19. <https://twitter.com/WHO/status/1240409217997189128> [cited 2020 May 4]
31. Therapeutic Goods Administration. No evidence to support claims ibuprofen worsens COVID-19 symptoms. Canberra: TGA; 2020 Mar 20. <https://www.tga.gov.au/alert/no-evidence-support-claims-ibuprofen-worsens-covid-19-symptoms> [cited 2020 May 4]
32. European Medicines Agency. EMA gives advice on the use of non-steroidal anti-inflammatories for COVID-19 [press release]. Amsterdam: EMA; 2020 Mar 18. <https://www.ema.europa.eu/en/news/ema-gives-advice-use-non-steroidal-anti-inflammatories-covid-19> [cited 2020 May 4]
33. Therapeutic Goods Administration. Amendments to the new restrictions on prescribing hydroxychloroquine for COVID-19. Canberra: TGA; 2020 Apr 6. <https://www.tga.gov.au/alert/amendments-new-restrictions-prescribing-hydroxychloroquine-covid-19> [cited 2020 May 4]
34. Pharmaceutical Benefits Scheme. PBS News: Revised hydroxychloroquine PBS listings for the treatment of autoimmune disorders and malaria from 1 May 2020. Canberra: Australian Government Department of Health; 2020 Apr 23. <http://www.pbs.gov.au/info/news/2020/05/revised-hydroxychloroquine-pbs-listings-for-the-treatment> [cited 2020 May 4]

Penicillin – getting prescribing right for children

SUMMARY

Penicillins are commonly prescribed to children. Recommendations in the product information may not be the most appropriate doses for children and may list clinical indications that are preferably treated with other antibiotics.

Reputable guidelines, for example Therapeutic Guidelines: Antibiotic, offer up-to-date advice on optimal choice, route, dosage and duration of oral penicillins in children.

In most instances, the child's weight should be used to calculate the dose in mg per kg without exceeding the maximum adult dose.

When prescribing higher weight-based doses of amoxicillin or flucloxacillin, check the volume of oral liquid required to complete a treatment course to ensure adequate supply.

Introduction

Rates of antibiotic prescribing and dispensing for infants and young children are higher than for any other age group under 65 years.¹ Penicillins such as amoxicillin and the combination amoxicillin/clavulanate are among the most commonly dispensed antibiotics in primary care.

When indicated, it is critical that the optimal antibiotic choice, dosage, regimen and duration are prescribed for children. Australian guidelines, including Therapeutic Guidelines: Antibiotic,² provide up-to-date recommendations for prescribing oral penicillins in children. GPs may instead choose to order the dose recommended in the product information as this is freely available online and integrated into many electronic prescribing systems.³ However, recommendations in the product information may not

be the most appropriate doses for children (see Box). It may only include indications and doses approved by the Therapeutic Goods Administration at registration. As most oral penicillin products in Australia have been used for more than 20 years and are generally off-patent, up-to-date dosing information may not be included in the product information, particularly for children.

Prescribing in children

Many childhood infections do not require antibiotics at all, including:

- common self-limiting infections
- viral infections
- bacterial infections that require drainage or other physical treatment (e.g. cutaneous abscess, dental infections requiring timely dental treatment).

Mona Mostaghim*

Quality use of medicines, medication safety and antimicrobial stewardship pharmacist¹

Brendan J McMullan*

Staff specialist, Infectious Diseases¹

Greg Rowles

General practitioner²

¹ Sydney Children's Hospital

² Riddells Creek, Vic.

* both these authors contributed equally

Keywords

antibiotics, antimicrobial stewardship, off-label use, penicillins, paediatrics

Aust Prescr 2020;43:81-4
<https://doi.org/10.18773/austprescr.2020.023>

Box Examples of prescribing pitfalls for oral penicillins in children

Amoxicillin

A 2-year-old child weighing 12 kg has mild-moderate pneumonia amenable to treatment with oral antibiotics. The dose recommended in Therapeutic Guidelines is 25 mg/kg/dose or 300 mg eight hourly.

The recommended dose in the product information would equate to 13.3 mg/kg/dose or 160 mg eight hourly. If this was followed the child would receive approximately half of the dose recommended by current guidelines.

Amoxicillin/clavulanic acid

A 5-year-old child weighing 20 kg has otitis media refractory to amoxicillin alone and is treated with amoxicillin/clavulanic acid. The dose recommended in Therapeutic Guidelines is a 7:1 ratio of 22.5 mg/kg of amoxicillin (450 mg) with 3.2 mg/kg clavulanic acid given 12 hourly.

The product information recommends the 4:1 formulation of amoxicillin:clavulanic acid at a dose of 13.3 mg/kg of amoxicillin (265 mg) and 3.3 mg/kg of clavulanic acid given eight hourly. This dosing and frequency is different from current guidelines and the excess clavulanic acid increases the risk of gastrointestinal adverse effects.

Flucloxacillin

A 3-year-old child weighing 15 kg is receiving oral flucloxacillin as step-down therapy for osteomyelitis after discharge from hospital. Therapeutic Guidelines recommend 25 mg/kg/dose or 375 mg six hourly.

The product information recommends 125 mg flucloxacillin six hourly which is approximately a third of the dose recommended in current guidelines.

Shared decision making with parents is an effective approach to appropriately using antibiotics and reducing antibiotic overuse.

‘Children are not little adults’ is a common comment from those working in paediatrics. The epidemiology, clinical presentation and prognosis of some infections differ in children compared to adults. Understanding this is key to timely diagnosis and good antimicrobial stewardship. In addition, pharmacokinetics can be different in children. This was evident with oral penicillins from the very beginning – gastric acid secretion, intestinal motility and drug pH all affect absorption. Depending on age and whether a child is unwell, these can result in net increased or decreased absorption compared to an adult. However, the magnitude of these effects are greatest during the first two years of life.⁴

In paediatric studies, dosage requirements often exceeded the expected dose for body size.^{4,5} Direct comparisons between paediatric studies were complicated by incomplete information about the age or weight of patients, use of different product strengths, teaspoon measures, and the ‘rounding’ of doses for convenient administration.^{4,6}

Empiric prescribing should ideally be based on the likely pathogen and the pharmacokinetics and pharmacodynamics of the antibiotic. Dosing information for children is included in Therapeutic Guidelines, the AMH Children’s Dosing Companion, and guidelines from children’s hospitals.

When a penicillin is required, it should be prescribed at doses that are expected to safely maximise the time that the drug remains above the minimum inhibitory concentration for the pathogen. If available, reviewing cultures and the results of susceptibility testing ensures the correct drug with the narrowest spectrum is used.

Narrow-spectrum penicillins are active against *Streptococcus pyogenes* (Group A streptococcus). Phenoxymethylpenicillin has been used extensively for erysipelas, streptococcal tonsillitis and dental infections that require antibiotics.

Amoxicillin is active against susceptible *Escherichia coli*. Adding the beta-lactamase inhibitor clavulanic acid increases the ability to treat certain Gram-negative organisms.

For *Streptococcus pneumoniae* infections (other than meningitis) with reduced susceptibility to penicillin, increasing the penicillin or amoxicillin dose may be effective. Using amoxicillin/clavulanic acid does not provide additional benefit in this case, as penicillin resistance in *Streptococcus pneumoniae* is not

mediated by a beta-lactamase.⁷ For mild to moderate pneumonia, oral amoxicillin is recommended in Therapeutic Guidelines at 25 mg/kg dose eight hourly and in World Health Organization guidelines⁸ at 40 mg/kg 12 hourly. It is non-inferior to parenteral options for this condition.

Amoxicillin/clavulanic acid is appropriate for treating beta-lactamase-producing strains of *Haemophilus influenzae* and *Moraxella catarrhalis*. If a higher amoxicillin dose is required, children aged two months and over should be prescribed a formulation with a lower dose of clavulanic acid.

Duration of therapy varies by indication. Many common, uncomplicated infections may be treated with shorter antibiotic courses than are commonly given.⁹

Dosing by age or weight – practical problems

In many instances it is unclear if dosing principles and recommended age bands in the product information are based on convenience or arise for other reasons – these fail to account for growth and metabolic development occurring within each age band. At the margins of age bands, for example at age six or 12 years, the average child¹⁰ might receive phenoxymethylpenicillin doses that either exceed the maximum or fail to meet the minimum dose for weight. For amoxicillin, this leads to substantial differences for children slightly above or below 20 kg.

Dose ranges are further widened for patients at the lowest and highest percentile weights for age, most obviously among 10–14 year-olds where the difference between the 5th and 90th percentile is greatest. Achieving adequate drug concentrations in overweight and obese patients is an increasing concern in countries such as Australia where around a quarter of children and adolescents (5–17 years) fall into this category.¹¹ Doses based only on age may be sub-therapeutic and result in treatment failure and an increased risk of resistance, or be excessively large doses based on a higher age band.¹² In most instances, the child’s weight should be used to calculate the dose in mg per kg without exceeding the maximum adult dose.

Volume and pack size

Discrepancies between the dose and duration recommended in the product information and guidelines introduce new problems.¹³ Older children may need additional tablets, and younger children may need a larger volume of oral liquid compared to what is provided in standard packs.¹⁴

Phenoxymethylpenicillin

When phenoxymethylpenicillin became available, doses in the range of 60 to 120 mg 3–6 hourly were commonly used for adults.^{15–17} Doses were generally halved for children, but for severe paediatric infections these half doses were often doubled.^{17–19} In the Australian product information, the same general principles continue to apply, which allow for a wide dose range. Twice-daily doses of phenoxymethylpenicillin for tonsillitis in children are not listed in the product information, even though this simplified regimen is commonly prescribed and reportedly achieves similar outcomes.²⁰ Therapeutic Guidelines recommends 15 mg/kg (up to 500 mg) 12-hourly phenoxymethylpenicillin for pharyngitis or tonsillitis requiring antibiotics.

Amoxicillin

Recommendations in the product information for amoxicillin suspensions – 250 mg/5 mL and 125 mg/5 mL – are generally unchanged from doses used in trials conducted in the 1970s. Paediatric doses are provided only for children weighing less than 20 kg.²¹ The product information recommends doses of 6.6 mg/kg eight hourly (20 mg/kg/day) with doubling of the dose for severe infections, for infections with less susceptible organisms or for lower respiratory tract infections. It is likely doses this low are often inadequate – data from the USA on acute otitis media suggest 83% of *Streptococcus pneumoniae* are susceptible to amoxicillin at 40 mg/kg/day.²² Twice-daily dosing at 60 mg/kg/day (given as 30 mg/kg/dose up to a maximum of 1 g 12 hourly) is licensed for use in acute otitis media in Australia. Prescribing amoxicillin for neonates remains off label in Australia, as are higher amoxicillin doses even though they have been studied and licensed overseas.²³ Therapeutic Guidelines² recommends 15 mg/kg doses eight hourly for urinary tract infections (with susceptible organisms) and 25 mg/kg eight hourly for pneumonia.

Amoxicillin/clavulanic acid

Clavulanic acid (clavulanate), a beta-lactamase inhibitor, is added to an amoxicillin backbone. Paediatric formulations of this combination in a

7:1 ratio (400 mg:57 mg in 5 mL) provide a higher amoxicillin component for indications such as acute otitis media. This optimises efficacy and minimises diarrhoea associated with too much clavulanic acid.²⁴ Despite this, products with a greater proportion of clavulanic acid (4:1, 125 mg:31.25 mg in 5 mL) continue to be recommended for children in the product information.

Flucloxacillin

Approved indications in Australia for flucloxacillin include pneumonia, and skin and bone infections. For children, the product information recommends prescribing half or a quarter of the adult dose depending on age. In early studies, flucloxacillin doses of 12.5 mg/kg for children produced similar concentrations to adults given doses of 500 mg. However, neonates had higher absorption than older children,²⁵ and infants aged under six months had better absorption than older children with liquid formulations.²⁶ Higher doses and weight-based doses that are recommended in many guidelines for bone infections in children are not included in the product information.

Conclusion

Evidence supporting optimal penicillin prescribing remains limited for children compared to adults. Dose recommendations available in the product information provide guidance which has often been superseded by regularly updated, evidence-based sources, such as Therapeutic Guidelines.

Prescribers should have access to evidence and updated guidelines to make decisions for children. Cooperation between regulators, pharmaceutical companies and software vendors is needed to improve this and support appropriate use of penicillins and other antimicrobials in the community. ◀

Brendan McMullan, Greg Rowles and Mona Mostaghim contributed to the most recent edition of eTG.

Brendan McMullan and Mona Mostaghim have also provided advice for sections of the AMH Children's Dosing Companion.

REFERENCES

1. Australian Commission on Safety and Quality in Health Care. AURA 2019 third Australian report on antimicrobial use and resistance in human health [Internet]. Sydney: ACSQHC; 2019. <https://www.safetyandquality.gov.au/our-work/antimicrobial-resistance/antimicrobial-use-and-resistance-australia-surveillance-system-aura/aura-2019> [cited 2020 May 1]
2. Antibiotic Expert Group. Antibiotic. In eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; 2019. <https://tgldcdp.tg.org.au> [cited 2020 May 1]
3. Day RO, Snowden L. Where to find information about drugs. *Aust Prescr* 2016;39:88–95. <https://doi.org/10.18773/austprescr.2016.023>
4. Doxiadis SA, Emery JL, Stewart SM. Oral penicillin in children. *BMJ* 1951;1:16–8. <https://doi.org/10.1136/bmj.1.4696.16>
5. Suchett-Kaye AI, Latter RB. Oral penicillin in young children. *BMJ* 1947;2:953. <https://doi.org/10.1136/bmj.2.4536.953>
6. Laurance B. Penicillin by mouth in infancy: a comparison between benzathine and sodium penicillins. *BMJ* 1954;2:1392–4. <https://doi.org/10.1136/bmj.2.4901.1392>

7. Sánchez Navarro A. New formulations of amoxicillin/clavulanic acid: a pharmacokinetic and pharmacodynamic review. *Clin Pharmacokinet* 2005;44:1097-115. <https://doi.org/10.2165/00003088-200544110-00001>
8. World Health Organization. Revised WHO classification and treatment of childhood pneumonia at health facilities: evidence summaries. Geneva: WHO; 2014. https://www.who.int/maternal_child_adolescent/documents/child-pneumonia-treatment/en [cited 2020 May 1]
9. Wilson HL, Daveson K, Del Mar CB. Optimal antimicrobial duration for common bacterial infections. *Aust Prescr* 2019;42:5-9. <https://doi.org/10.18773/austprescr.2019.001>
10. Centers for Disease Control and Prevention. CDC growth charts. [Internet] Atlanta (GA) CDC; 2016. https://www.cdc.gov/growthcharts/cdc_charts.htm [cited 2020 May 1]
11. Australian Institute of Health and Welfare. Who is overweight? In: Risk factors to health – Overweight and obesity [Internet]. Canberra: AIHW; 2018. <https://www.aihw.gov.au/reports/risk-factors/risk-factors-to-health/contents/overweight-and-obesity/who-is-overweight> [updated 2018 Dec 18; cited 2020 May 1]
12. Gade C, Christensen HR, Dalhoff KP, Holm JC, Holst H. Inconsistencies in dosage practice in children with overweight or obesity: a retrospective cohort study. *Pharmacol Res Perspect* 2018;6:e00398. <https://doi.org/10.1002/prp2.398>
13. McGuire TM. Does size matter? Addressing pack size and antibiotic duration. *Aust Prescr* 2019;42:2-3. <https://doi.org/10.18773/austprescr.2019.005>
14. Committee for medicinal products for human use (CHMP). Reflection paper: formulations of choice for the paediatric population. London: European Medicines Agency; 2006. <https://www.ema.europa.eu/en/formulations-choice-paediatric-population> [cited 2020 May 1]
15. Penicillin V. *BMJ* 1957;2:207-8. <https://doi.org/10.1136/bmj.2.5038.207>
16. Hart FD, Burley D, Manley R, Brown G, Penicillin V. Penicillin V. *BMJ* 1956;1:496-7. <https://doi.org/10.1136/bmj.1.4965.496>
17. Wheatley D. Oral penicillin in general practice. *BMJ* 1958;2:907-9. <https://doi.org/10.1136/bmj.2.5101.907>
18. Bowerbank AG. Phenoxymethyl penicillin. *Br Med J* 1955;2:1028-9. <https://doi.org/10.1136/bmj.2.4946.1028-c>
19. Pharmaceutical Association of Australia. Australian pharmaceutical formulary APF. 10th ed. Victoria; 1969.
20. Lan AJ, Colford JM, Colford JM Jr. The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: a meta-analysis. *Pediatrics* 2000;105:e19. <https://doi.org/10.1542/peds.105.2.e19>
21. Wise PJ, Neu HC. Experience with amoxicillin: an overall summary of clinical trials in the United States. *J Infect Dis* 1974;129(Suppl 2):S266-71. https://doi.org/10.1093/infdis/129.Supplement_2.S266
22. Lieberthal AS, Carroll AE, Chonmaitree T, Ganiats TG, Hoberman A, Jackson MA, et al. The diagnosis and management of acute otitis media. *Pediatrics* 2013;131:e964-99. <https://doi.org/10.1542/peds.2012-3488>
23. Amoxicillin. In: McEvoy GK, editor. AHFS Drug Information 2020 [Internet]. Bethesda (MD): American Society of Health-System Pharmacists; 2020. <http://www.ahfsdruginformation.com> [cited 2020 May 1]
24. Kuehn J, Ismael Z, Long PF, Barker CI, Sharland M. Reported rates of diarrhea following oral penicillin therapy in pediatric clinical trials. *J Pediatr Pharmacol Ther* 2015;20:90-104. <https://doi.org/10.5863/1551-6776-20.2.90>
25. Bergdahl S, Eriksson M, Finkel Y. Plasma concentration following oral administration of di- and flucloxacillin in infants and children. *Pharmacol Toxicol* 1987;60:233-4. <https://doi.org/10.1111/j.1600-0773.1987.tb01741.x>
26. Bergdahl S, Eriksson M, Finkel Y, Lännergren K. Oral absorption of flucloxacillin in infants and young children. *Acta Pharmacol Toxicol (Copenh)* 1986;58:255-8. <https://doi.org/10.1111/j.1600-0773.1986.tb00105.x>

FURTHER READING

Antibiotic prescribing in primary care: Therapeutic Guidelines summary table 2019. In: eTG complete [digital]. Melbourne: Therapeutic Guidelines Guidelines Limited; 2020. <https://tgldcdp.tg.org.au/etgAccess> [cited 2020 May 1]

Australasian Society for Infectious Diseases [Internet]. <https://www.asid.net.au/groups/anzpid> [cited 2020 May 1] [Provides additional resources]

Australian Commission on Safety and Quality in Healthcare. Decision support tools for patients [Internet]. 2019. <https://www.safetyandquality.gov.au/our-work/partnering-consumers/shared-decision-making/decision-support-tools-patients> [cited 2020 May 1]

AMH Children's dosing companion. Adelaide: Australian Medicines Handbook; 2020. <https://childrens.amh.net.au/auth> [cited 2020 May 1]

McMullan BJ, Andresen D, Blyth CC, Avent ML, Bowen AC, Britton PN, et al.; ANZPID-ASAP group. Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines. *Lancet Infect Dis* 2016;16:e139-52. [https://doi.org/10.1016/S1473-3099\(16\)30024-X](https://doi.org/10.1016/S1473-3099(16)30024-X)

Treatment of systemic lupus erythematosus

SUMMARY

Systemic lupus erythematosus should be suspected in individuals with one or more classic symptoms. Diagnosis is made clinically and supported by serology.

Reducing sun exposure is central to the management of lupus.

Hydroxychloroquine is first-line treatment unless contraindicated and is useful in almost all manifestations of lupus. Other treatments are titrated against type and severity of organ involvement.

Monoclonal antibodies have a limited role in the management of lupus.

Introduction

Systemic lupus erythematosus (also known as lupus) is a chronic, relapsing-remitting autoimmune disease characterised by autoantibody production. It may present at any stage of life, but is most common in women of childbearing age, with a female to male ratio of 9:1. Lupus has a wide spectrum of presentations, including skin, psychiatric and kidney manifestations.

When to suspect lupus

Lupus should be considered in any individual with one or more typical manifestations, but especially women of childbearing age. Classic symptoms include photosensitive rash, mouth ulcers, small joint arthritis, or unexplained cytopenias and venous or arterial clotting. Serositis and neurologic involvement are observed less commonly (Box).¹

How to confirm diagnosis

The variable manifestations of lupus make diagnosis difficult and serology can be useful (see Box). Almost all patients (99%) have antinuclear antibodies at diagnosis. However, they are nonspecific and present in approximately 5% of the healthy population at titres of 1:320.² More specific for lupus is the presence of anti-double-stranded DNA antibodies, particularly when detected by the radionucleotide Farr assay. These are observed in approximately 70% of patients with lupus.³ Anti-Smith antibodies are uncommon but specific for lupus and associated with nephritis and cytopenias.⁴ Antiphospholipid antibodies are found in 40% of patients and are classically associated with an elevated risk of thrombosis and miscarriage.⁵ Antibodies against the extractable nuclear antigens Ro(SSA), La(SSB) and ribonuclear protein are common but nonspecific in the diagnosis of lupus. Antinuclear antibodies combined with lupus-specific antibody positivity can support the diagnosis. These

are incorporated in the Systemic Lupus International Collaborating Clinics diagnostic criteria (Box).¹

Pathogenesis

The pathogenesis of lupus is a composite of complex genetic risk and environmental influences. While immunologic abnormalities ranging from complement to B-cell dysregulation are reported, increased type 1 interferon activity is observed in 85% of patients at any point in time.⁶ This is central to the disease. Reflecting this complex pathogenesis, several distinct biologic pathways have been targeted in the treatment of lupus.

Management of lupus

The management of lupus includes three goals:

- preventing flares and their symptomatic impact
- reducing chronic accumulation of organ damage
- minimising toxicity from immunosuppression.

All patients should minimise sun exposure and use hydroxychloroquine unless contraindicated. For lupus activity that is resistant to these measures, antiproliferative immunosuppressants and corticosteroids are effective. The choice of antiproliferative is influenced by the organ involved. Cyclophosphamide is used for severe life- and organ-threatening lupus. Biologic drugs have a limited role but drugs such as rituximab may be used for manifestations refractory to other treatments.

Non-drug approaches

Ultraviolet exposure can flare both cutaneous and systemic symptoms such as arthritis. Sunscreens (SPF 50+) should be used as well as avoiding exposure during peak hours.⁷

Smoking cessation may help with treatment-resistant skin lesions.⁸ It may also mitigate the elevated cardiovascular risk associated with lupus.⁹

Kathryn P McKeon

Research fellow¹

Simon H Jiang

Consultant nephrologist¹

Postdoctoral fellow²

¹ Department of Renal Medicine, The Canberra Hospital

² Department of Immunology and Infectious Diseases, John Curtin School of Medical Research, Australian National University
Canberra

Keywords

corticosteroids, hydroxychloroquine, immunosuppressants, systemic lupus erythematosus

Aust Prescr 2020;43:85–90

<https://doi.org/10.18773/austprescr.2020.022>

Box **Diagnostic criteria for systemic lupus***

Clinical criteria

Acute cutaneous – lupus malar rash, bullous lupus, toxic epidermal necrolysis variant of lupus, maculopapular lupus rash, photosensitive lupus rash

Chronic cutaneous – discoid lupus rash, hypertrophic (verrucous) lupus, lupus panniculitis, mucosal lupus, lupus erythematosus tumidus, chilblains lupus, discoid lupus

Oral or nasal ulcers – palate, buccal, tongue, or nasal in the absence of other causes

Non-scarring alopecia – in the absence of other causes

Arthritis – synovitis involving 2 or more joints, characterised by swelling or effusion or tenderness in 2 or more joints and at least 30 minutes of morning stiffness

Serositis – typical pleurisy for more than one day, pleural effusions, pleural rub or typical pericardial pain for more than one day, pericardial effusion, pericardial rub or pericarditis by ECG

Renal involvement – urine protein:creatinine ratio or 24-hour urine protein with >500 mg protein/24 hours or red cell casts

Neurological symptoms – seizures, psychosis, mononeuritis multiplex, myelitis, peripheral or cranial neuropathy, acute confusional state

Haemolytic anaemia – in the absence of other causes

Leucopenia – in the absence of other causes

Thrombocytopenia – in the absence of other causes

Immunological criteria

Antinuclear antibodies

Anti-dsDNA antibodies – above reference range (or >2-fold if tested by ELISA)

Anti-Smith antibodies

Antiphospholipid antibodies – positive lupus anticoagulant, false-positive rapid plasma reagin test, medium- or high-titre cardiolipin antibody, positive anti-b2-glycoprotein

Low complement C3, C4, CH50

Positive Direct Coombs test – in the absence of haemolytic anaemia

* For a positive diagnosis, patients must have 4 or more of the listed criteria, with at least 1 clinical and 1 laboratory criterion

dsDNA double-stranded DNA

ELISA enzyme-linked immunosorbent assay

Source: reference 1

doses (400 mg daily).¹⁶ In addition to improving skin symptoms, hydroxychloroquine reduces flares of systemic lupus¹⁷ and lupus nephritis.¹⁸ It also lowers cholesterol and thromboembolic risk in patients with antiphospholipid antibodies.^{19,20} Consequently, sustained hydroxychloroquine therapy minimises accrual of organ damage²¹ and glucocorticoid-induced osteoporosis, and improves overall survival.²²

The major complications of hydroxychloroquine therapy are ocular. Transient and reversible corneal deposits occur in about 10% of people.²³ Irreversible retinopathy can also develop and typically manifests as visual disturbances, photophobia or light flashes. The risk of retinal toxicity is cumulative and may be as high as 20% at 20 years with recommended hydroxychloroquine doses.²⁴ A maximal daily hydroxychloroquine dose of less than 5 mg/kg (up to 400 mg/day) is recommended, along with regular screening by an ophthalmologist to detect toxicity before visual changes (Table 1).²⁴⁻²⁶ Less common adverse effects include cardiac, cutaneous and neuropsychiatric manifestations.²⁷ Hydroxychloroquine is safe to use in pregnancy and should be continued.²⁸

Corticosteroids

Almost all patients will be treated with corticosteroids at some point.²⁹ They are effective in controlling systemic lupus but their sustained use is limited by substantial toxicity. Corticosteroids are used transiently to control systemic disease flares or when disease activity cannot be controlled by other drugs alone. Due to toxicity, they should never be used on their own.

The adverse effects are dose-dependent and include an increased risk of infection, cancer, osteoporosis and avascular necrosis, steroid-induced diabetes, accelerated atherosclerosis and mood disturbances.³⁰ Cardiovascular risk is significantly increased in lupus and the use of corticosteroids increases this further.³¹ Indeed, no study has established a safe lowest dose in systemic lupus so when possible they should be withdrawn.³²

The toxicity of corticosteroids needs to be balanced against the threat of organ injury if they are not used. For mild disease, lower doses are often sufficient. High doses are typically reserved for debilitating or life-threatening involvement such as lupus nephritis or neuropsychiatric lupus (Table 2).³³ Once disease remission is achieved, the dose should be tapered.

For cutaneous lesions, topical corticosteroids are the mainstay of treatment. Higher potency creams have superior efficacy over low-potency creams.³⁴ However, they increase the risks of telangiectasia and skin atrophy and are used intermittently depending on the severity and location of the lesions. Topical steroids are useful for mouth ulcers but increase the risk of candidiasis.

Non-steroidal anti-inflammatory drugs

Non-steroidal anti-inflammatory drugs (NSAIDs) are effective for symptom relief in lupus-associated arthritis and myalgias.¹⁰ However, they increase the risk of allergic reactions¹¹ and aseptic meningitis.¹² In the presence of lupus nephritis, they increase the risk of acute kidney injury¹³ and death when used in patients with end-stage kidney disease.¹⁴

Hydroxychloroquine

Hydroxychloroquine should be used in all patients with lupus unless contraindicated. It is an antimalarial drug that inhibits toll-like receptors 7 and 9. These are potent drivers of type 1 interferon production.¹⁵ Hydroxychloroquine is useful in both cutaneous and systemic lupus. Approximately half of patients with cutaneous lupus fail to respond to standard doses (200 mg daily) and may benefit from higher

Table 1 Monitoring for patients receiving lupus treatments

Drug	Monitoring
Hydroxychloroquine	Baseline fundal exam of the eye, then annual screening after 5 years treatment ²⁴
Corticosteroids	Baseline and annual bone densitometry ³ Annual diabetes check ^{3,25} Periodic ophthalmology review for cataracts and glaucoma
Azathioprine	TMPT activity before starting treatment Full blood count at 2–4 weeks for 2–3 months, then every 3 months
Methotrexate	Full blood count and liver function test every 2–4 weeks for 3 months, then every 2–3 months until 6 months. Monitor every 3 months when patient is stable ^{7,26}
Mycophenolate	Full blood count at 2–4 weeks, then every 3 months
Cyclophosphamide	Full blood count every 2 weeks for a month, then monthly
Rituximab	Optional: check CD19+ B cells to confirm depletion

TMPT thiopurine methyltransferase

Table 2 Steroid doses and indications in lupus

EULAR grading	Dose: prednisolone equivalent (mg)	Typical indications	Duration and tapering
Low dose	<7.5	Maintenance	If starting on low dose, give for 2–4 weeks. Tapering not required
Medium dose	7.5–30	Mild disease: cutaneous, musculoskeletal, haematological, or constitutional symptoms	Medium–high dose for 2–4 weeks then taper over 1–2 months
High dose	30–100		
Very high dose	>100	Induce remission of severe disease	
Pulse therapy	>250		

EULAR European League Against Rheumatism
Source: reference 33

Antiproliferative drugs

Three antiproliferative immunosuppressants are primarily used in systemic lupus – azathioprine, methotrexate and mycophenolate. For non-renal manifestations such as arthritis and rash where hydroxychloroquine or topical corticosteroids are insufficient, methotrexate is effective.³⁵ While evidence is stronger for methotrexate, azathioprine is also useful and has the benefit of being safe in pregnancy. Thiopurine methyltransferase activity should be tested before azathioprine is used to avoid bone marrow suppression in patients with a deficiency.

Mycophenolate is effective in non-renal disease that is refractory to corticosteroids,³⁶ and is superior

to azathioprine.³⁷ However, it is contraindicated in pregnancy. For systemic lupus with kidney involvement, mycophenolate is superior to azathioprine so it is first-line maintenance therapy when tolerated.³⁸

Cyclophosphamide

Cyclophosphamide is an alkylating drug that is beneficial in treating severe lupus. Oral regimens result in higher cyclophosphamide exposure and carry a greater risk of infection and bone marrow suppression than the intravenous preparation. High-dose mycophenolate is as effective as cyclophosphamide in controlling aggressive nephritis and is increasingly used as first-line therapy³⁸ given the lower rates of hair loss and infertility.

Biologic drugs

A range of new biological therapies has been investigated in patients with lupus. Many have not shown significant benefit to date.³⁹⁻⁴⁸

Rituximab

Rituximab is a B-cell depleting antibody against CD20. Despite initial reports of excellent responses to this drug, trials have failed to show a benefit in non-renal³⁹ and renal lupus.⁴⁰ However, it continues to be used in refractory disease and registry data suggest a benefit.^{49,50}

Belimumab

Belimumab antibody inhibits B-cell activating factor (BAFF). This target has shown significant pre-clinical promise given its role in promoting autoreactive B-cell activation and proliferation.⁵¹ Two multicentre trials, BLISS-52⁴³ and BLISS-76,⁴⁴ assessed the efficacy of belimumab at 52 and 76 weeks. While reaching statistical significance, both trials observed a modest reduction in overall disease activity at 52 weeks and no significant benefit at 76 weeks. The benefit was largely due to improvements in musculoskeletal and cutaneous symptoms.⁵² Its role in non-renal disease that is unresponsive to conventional drugs.

Anifrolumab

Anifrolumab blocks the interferon alpha receptor 1. Initial lupus studies observed benefits in disease activity. However, placebo-controlled trials (TULIP 1 and TULIP 2) failed to demonstrate benefit when conventional measures of lupus activity were used, and only marginally significant benefit when modified lupus scores were used.^{53,54}

Pregnancy

Pregnancy can present challenges in women with lupus, so pregnancy planning and counselling are important.⁵⁵ Fertility rates are normal in lupus, unless compromised by cyclophosphamide⁵⁶ or worsening renal failure. Recent evidence is conflicting regarding increased disease flares during pregnancy.^{57,58} However, the risks of pre-eclampsia⁵⁹ and miscarriage⁶⁰ are significantly higher. Secondary antiphospholipid syndrome confers added perinatal risk warranting specialist care.

When treating pregnant women, corticosteroids and azathioprine are generally safe. Mycophenolate, methotrexate and cyclophosphamide are contraindicated in pregnancy. Cyclophosphamide should be stopped three months before attempting to conceive and both men and women receiving cyclophosphamide should be on appropriate contraception. Egg harvesting or sperm banking should be considered before treatment.

Conclusion

Lupus has a wide range of clinical manifestations and should be considered as a diagnosis when two or more symptoms occur in women of childbearing age. All patients should receive hydroxychloroquine with appropriate monitoring. Antiproliferative drugs are useful for maintenance therapy, while high-dose steroids and cyclophosphamide are reserved for severe disease. The role of biologic drugs is an area of ongoing research. <

Conflict of interest: none declared

REFERENCES

- Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 2012;64:2677-86. <https://doi.org/10.1002/art.34473>
- Sjöwall C, Sturm M, Dahle C, Bengtsson AA, Jönsen A, Sturfelt G, et al. Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus. *J Rheumatol* 2008;35:1994-2000.
- Villalta D, Bizzaro N, Bassi N, Zen M, Gatto M, Ghirardello A, et al. Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. *PLoS One* 2013;8:e71458. <https://doi.org/10.1371/journal.pone.0071458>
- Arroyo-Ávila M, Santiago-Casas Y, McGwin G Jr, Cantor RS, Petri M, Ramsey-Goldman R, et al. Clinical associations of anti-Smith antibodies in PROFILE: a multi-ethnic lupus cohort. *Clin Rheumatol* 2015;34:1217-23. <https://doi.org/10.1007/s10067-015-2941-y>
- Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. *Arthritis Rheum* 2009;61:29-36. <https://doi.org/10.1002/art.24232>
- Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, et al. Personalized immunomonitoring uncovers molecular networks that stratify lupus patients. *Cell* 2016;165:1548-50. <https://doi.org/10.1016/j.cell.2016.05.057>
- Kuhn A, Gensch K, Haust M, Meuth AM, Boyer F, Dupuy P, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: a randomized, vehicle-controlled, double-blind study. *J Am Acad Dermatol* 2011;64:37-48. <https://doi.org/10.1016/j.jaad.2009.12.053>
- Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. *J Am Acad Dermatol* 2000;42:983-7. <https://doi.org/10.1067/mjd.2000.103635>
- Esdale JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. *Arthritis Rheum* 2001;44:2331-7. [https://doi.org/10.1002/1529-0131\(200110\)44:10<2331::AID-ART395>3.0.CO;2-I](https://doi.org/10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I)
- Wallace DJ, Metzger AL, Klinenberg JR. NSAID usage patterns by rheumatologists in the treatment of SLE. *J Rheumatol* 1989;16:557-60.
- Wang CR, Chuang CY, Chen CY. Drug allergy in Chinese patients with systemic lupus erythematosus. *J Rheumatol* 1993;20:399-400.

12. Agus B, Nelson J, Kramer N, Mahal SS, Rosenstein ED. Acute central nervous system symptoms caused by ibuprofen in connective tissue disease. *J Rheumatol* 1990;17:1094-6.
13. Østensen M, Villiger PM. Nonsteroidal anti-inflammatory drugs in systemic lupus erythematosus. *Lupus* 2000;9:566-72. <https://doi.org/10.1191/096120300678828794>
14. Lai KM, Chen TL, Chang CC, Chen HH, Lee YW. Association between NSAID use and mortality risk in patients with end-stage renal disease: a population-based cohort study. *Clin Epidemiol* 2019;11:429-41. <https://doi.org/10.2147/CLEP.S204322>
15. Kuźnik A, Bencina M, Svajger U, Jeras M, Rozman B, Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. *J Immunol* 2011;186:4794-804. <https://doi.org/10.4049/jimmunol.1000702>
16. Chasset F, et al. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): an open-label prospective pilot study. *J Am Acad Dermatol* 2016;74:693-9. <https://doi.org/10.1016/j.jaad.2015.09.064>.
17. Mok CC, Penn HJ, Chan KL, Tse SM, Langman LJ, Jannetto PJ. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. *Arthritis Care Res (Hoboken)* 2016;68:1295-302. <https://doi.org/10.1002/acr.22837>
18. Cunha C, Alexander S, Ashby D, Lee J, Chusney G, Cairns TD, et al. Hydroxycycloquine blood concentration in lupus nephritis: a determinant of disease outcome? *Nephrol Dial Transplant* 2018;33:1604-10. <https://doi.org/10.1093/ndt/gfx318>
19. Wallace DJ, Linker-Israeli M, Metzger AL, Stecher VJ. The relevance of antimalarial therapy with regard to thrombosis, hypercholesterolemia and cytokines in SLE. *Lupus* 1993;2 Suppl 1:3-5. <https://doi.org/10.1177/0961203393002001041>
20. Broder A, Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. *J Rheumatol* 2013;40:30-3. <https://doi.org/10.3899/jrheum.120157>
21. Akhavan PS, Su J, Lou W, Gladman DD, Urowitz MB, Fortin PR. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus. *J Rheumatol* 2013;40:831-41. <https://doi.org/10.3899/jrheum.120572>
22. Alarcón GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alén J, Bastian HM, et al.; LUMINA Study Group. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). *Ann Rheum Dis* 2007;66:1168-72. <https://doi.org/10.1136/ard.2006.068676>
23. Easterbrook M. Is corneal deposition of antimalarial any indication of retinal toxicity? *Can J Ophthalmol* 1990;25:249-51.
24. Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). *Ophthalmology* 2016;123:1386-94. <https://doi.org/10.1016/j.ophtha.2016.01.058>
25. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgerit F, Caeyers N, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. *Ann Rheum Dis* 2007;66:1560-7. <https://doi.org/10.1136/ard.2007.072157>
26. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC, et al. 2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis. *Arthritis Rheumatol* 2016;68:1-26. <https://doi.org/10.1002/art.39480>
27. Soria A, Barbaud A, Assier H, Avenel-Audran M, Tétart F, Raison-Peyron N, et al.; FISARD (French Investigators for Skin Adverse Reaction to Drugs). Cutaneous adverse drug reactions with antimalarials and allergological skin tests. *Dermatology* 2015;231:353-9. <https://doi.org/10.1159/000438787>
28. Costedoat-Chalumeau N, Amoura Z, Duhaut P, Huong DL, Sebbough D, Wechsler B, et al. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases: a study of one hundred thirty-three cases compared with a control group. *Arthritis Rheum* 2003;48:3207-11. <https://doi.org/10.1002/art.11304>
29. Zonana-Nacach A, Barr SG, Magder LS, Petri M. Damage in systemic lupus erythematosus and its association with corticosteroids. *Arthritis Rheum* 2000;43:1801-8. [https://doi.org/10.1002/1529-0131\(200008\)43:8<1801::AID-ANR16>3.0.CO;2-O](https://doi.org/10.1002/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O)
30. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. *Allergy Asthma Clin Immunol* 2013;9:30. <https://doi.org/10.1186/1710-1492-9-30>
31. Magder LS, Petri M. Incidence of and risk factors for adverse cardiovascular events among patients with systemic lupus erythematosus. *Am J Epidemiol* 2012;176:708-19. <https://doi.org/10.1093/aje/kws130>
32. van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerström K, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. *Ann Rheum Dis* 2014;73:958-67. <https://doi.org/10.1136/annrheumdis-2013-205139>
33. Buttgerit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. *Ann Rheum Dis* 2002;61:718-22. <https://doi.org/10.1136/ard.61.8.718>
34. Kuhn A, Ruland V, Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. *J Am Acad Dermatol* 2011;65:e179-93. <https://doi.org/10.1016/j.jaad.2010.06.018>
35. Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. *Lupus* 2014;23:225-35. <https://doi.org/10.1177/0961203313519159>
36. Ginzler EM, Wofsy D, Isenberg D, Gordon C, Lisk L, Dooley MA; ALMS Group. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial. *Arthritis Rheum* 2010;62:211-21. <https://doi.org/10.1002/art.25052>
37. Ordi-Ros J, Sáez-Comet L, Pérez-Conesa M, Vidal X, Mitjavila F, Castro Salomó A, et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. *Ann Rheum Dis* 2017;76:1575-82. <https://doi.org/10.1136/annrheumdis-2016-210882>
38. Tunncliffe DJ, Palmer SC, Henderson L, Masson P, Craig JC, Tong A, et al. Immunosuppressive treatment for proliferative lupus nephritis. *Cochrane Database Syst Rev* 2018;6:CD002922. <https://doi.org/10.1002/14651858.CD002922.pub4>
39. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. *Arthritis Rheum* 2010;62:222-33. <https://doi.org/10.1002/art.27233>
40. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al.; LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. *Arthritis Rheum* 2012;64:1215-26. <https://doi.org/10.1002/art.34359>
41. Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. *Arthritis Rheum* 2013;65:2368-79. <https://doi.org/10.1002/art.38037>
42. Schindler T, Rovin B, Furie R, Leandro M, Clark M, Brunetta J, et al. ABO423 NOBILITY, a phase 2 trial to assess the safety and efficacy of obinutuzumab, a novel type 2 anti-CD20 monoclonal antibody (mAb), in patients (pts) with ISN/RPS class III or IV lupus nephritis (LN). *Ann Rheum Dis* 2016;75:1051. <https://doi.org/10.1136/annrheumdis-2016-eular.2397>
43. Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al.; BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet* 2011;377:721-31. [https://doi.org/10.1016/S0140-6736\(10\)61354-2](https://doi.org/10.1016/S0140-6736(10)61354-2)

44. Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, et al.; BLISS-76 Study Group. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. *Arthritis Rheum* 2011;63:3918-30. <https://doi.org/10.1002/art.30613>
45. Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). *Ann Rheum Dis* 2015;74:2006-15. <https://doi.org/10.1136/annrheumdis-2013-205067>
46. Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW, et al. Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. *Ann Rheum Dis* 2016;75:323-31. <https://doi.org/10.1136/annrheumdis-2015-207653>
47. Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M, et al. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. *Ann Rheum Dis* 2016;75:332-40. <https://doi.org/10.1136/annrheumdis-2015-207654>
48. McBride JM, Jiang J, Abbas AR, Morimoto A, Li J, Maciura R, et al. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. *Arthritis Rheum* 2012;64:3666-76. <https://doi.org/10.1002/art.34632>
49. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, et al.; Club Rhumatismes et Inflammation. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. *Arthritis Rheum* 2010;62:2458-66. <https://doi.org/10.1002/art.27541>
50. Iaccarino L, Bartoloni E, Carli L, Ceccarelli F, Conti F, De Vita S, et al. Efficacy and safety of off-label use of rituximab in refractory lupus: data from the Italian Multicentre Registry. *Clin Exp Rheumatol* 2015;33:449-56.
51. Mackay F, Woodcock SA, Lawton P, Ambrose C, Baetscher M, Schneider P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. *J Exp Med* 1999;190:1697-710. <https://doi.org/10.1084/jem.190.11.1697>
52. Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al.; BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. *Ann Rheum Dis* 2012;71:1833-8. <https://doi.org/10.1136/annrheumdis-2011-200831>
53. Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. *Lancet Rheumatol* 2019;1:e208-19. [https://doi.org/10.1016/S2665-9913\(19\)30076-1](https://doi.org/10.1016/S2665-9913(19)30076-1)
54. Morand EF, Furie R, Tanaka Y, Bruce IN, Askanase AD, Richez C, et al.; TULIP-2 Trial Investigators. Trial of anifrolumab in active systemic lupus erythematosus. *N Engl J Med* 2020;382:211-21. <https://doi.org/10.1056/NEJMoa1912196>
55. Paizis K. Immunomodulatory drugs in pregnancy and lactation. *Aust Prescr* 2019;42:97-101. <https://doi.org/10.18773/austprescr.2019.026>
56. Langevitz P, Klein L, Pras M, Many A. The effect of cyclophosphamide pulses on fertility in patients with lupus nephritis. *Am J Reprod Immunol* 1992;28:157-8. <https://doi.org/10.1111/j.1600-0897.1992.tb00780.x>
57. Wong KL, Chan FY, Lee CP. Outcome of pregnancy in patients with systemic lupus erythematosus. A prospective study. *Arch Intern Med* 1991;151:269-73. <https://doi.org/10.1001/archinte.1991.00400020043010>
58. Urowitz MB, Gladman DD, Farewell VT, Stewart J, McDonald J. Lupus and pregnancy studies. *Arthritis Rheum* 1993;36:1392-7. <https://doi.org/10.1002/art.1780361011>
59. Julkunen H, Kaaja R, Palosuo T, Grönhagen-Riska C, Teramo K. Pregnancy in lupus nephropathy. *Acta Obstet Gynecol Scand* 1993;72:258-63. <https://doi.org/10.3109/00016349309068034>
60. Nossent HC, Swaak TJ. Systemic lupus erythematosus. VI. Analysis of the interrelationship with pregnancy. *J Rheumatol* 1990;17:771-6.

Lithium therapy and its interactions

SUMMARY

Lithium is one of the most effective mood stabilisers for people with a mood disorder. However, many of these patients are also taking other medicines that could potentially interact with lithium.

To minimise the risk of relapse, it is usually necessary to maintain the lithium serum concentration between 0.6 mmol/L and 0.8 mmol/L.

Lithium clearance is easily influenced by drugs that alter renal function such as ACE inhibitors, angiotensin receptor antagonists, diuretics, and non-steroidal anti-inflammatory drugs.

It is therefore prudent for prescribers to monitor and adjust the lithium dose to avoid adverse effects or loss of efficacy.

Introduction

Driven by new research reinforcing the unique benefits of lithium, there has been a worldwide resurgence in the prescription of lithium. In clinical practice it is used predominantly to stabilise mood.¹ It remains one of the most effective options for bipolar disorder,² along with the newer atypical antipsychotics.³ Lithium also serves as an effective adjunctive option for recurrent or resistant major depressive disorder and has anti-suicidal properties which are invaluable in the management of mood disorders.

Lithium is simple to administer and is usually well tolerated. Routine management of patients receiving lithium monotherapy is relatively straightforward.⁴ However, complications can arise when other drugs are added that could potentially interact with lithium. Regular monitoring of lithium plasma concentrations and other safety parameters is essential. Results should be communicated to the patient and everyone involved in their care. Aids are available to assist prescribers with lithium management, including an Australian tool called the 'Lithiumeter'.⁴

Indications for lithium

Patients with classic, episodic and remitting bipolar disorder with a family history and no psychiatric comorbidity are most likely to respond to lithium. Typically, lithium is effective in about a third of patients – with response rates up to two-thirds in those whose relatives have achieved good responses.⁵ It is likely that people who commence lithium early in the course of their illness may have greater likelihood of response. In major depressive disorder, lithium is used to augment antidepressant drugs.

Lithium monitoring

Lithium has a very narrow therapeutic window for maintenance therapy. Too little lithium risks undertreatment of the mood disorder and increases the risk of relapse. Too much lithium increases the risk of both acute and chronic toxicity. Lithium concentrations should always be measured 12 hours after the last dose.

For the maintenance phase of treatment, recent guidelines recommend that patients maintain a serum concentration of 0.6–0.8 mmol/L to maximise therapeutic benefit.⁶ For acute treatment in mania, serum concentrations should be increased to 0.6–1.0 mmol/L as tolerated. In depression, concentrations can be in the range of 0.4–0.8 mmol/L. In practice, target concentrations and monitoring practices are often inconsistent. Not all pathology laboratories use the same reference ranges, therefore noting whether the lithium concentration is consistent with the patient's presentation and the guidelines is essential.

As a part of optimising lithium dosing, clinicians may notice that a specific concentration achieves the most therapeutic benefit during euthymic periods and during manic and depressive episodes. Taking note of this is essential and helps to ensure stability of these patient-specific concentrations over time, particularly during each illness phase.

Maintenance of the therapeutic concentration (and adherence) is the strongest predictor of long-term stability. However, in some patients, stabilising their mood is not always possible with lithium alone. A trial with other mood stabilisers, such as adjunctive sodium valproate or an atypical antipsychotic, is often necessary.

Gin S Malhi^{1,2,3}
Erica Bell^{1,2,3}
Tim Outhred^{1,2,3}
Michael Berk^{4,5,6,7}

¹ Discipline of Psychiatry, Northern Clinical School, University of Sydney

² Department of Academic Psychiatry, Northern Sydney Local Health District

³ CADE Clinic, Royal North Shore Hospital, Northern Sydney Local Health District

⁴ IMPACT – the Institute for Mental and Physical Health and Clinical Translation, School of Medicine, Barwon Health, Deakin University, Geelong, Vic.

⁵ Department of Psychiatry, University of Melbourne, Royal Melbourne Hospital

⁶ Florey Institute for Neuroscience and Mental Health, University of Melbourne

⁷ Orygen, The National Centre of Excellence in Youth Mental Health, Melbourne

Keywords

bipolar disorder, lithium, mood disorders

Aust Prescr 2020;43:91–3
<https://doi.org/10.18773/austprescr.2020.024>

Corrected 12 June 2020

This is the corrected version of the article.

Correction notice available at:
<https://doi.org/10.18773/austprescr.2020.041>

Box Monitoring schedule for lithium therapy

Baseline assessments and follow-up of patients should be performed:

- during the early maintenance phase (e.g. baseline, 7 days, 14 days and 28 days) then at 3, 6 and 12 months, then annually

and

- when there are any changes in presentation
- following abnormal findings
- when altering the treatment regimen.

Regularly check the following:

- serum lithium concentrations and mood and stability over time
- renal function
 - electrolytes, urea, creatinine
 - estimated glomerular filtration rate
- thyroid and parathyroid function
 - thyroid stimulating hormone
 - calcium
- blood and cardiometabolic tests
 - full blood count, glucose, lipids, liver function tests
 - ECG
 - weight, BMI, umbilical girth
 - diet and eating behaviour
 - exercise and hydration
 - other comorbidities
- adverse effects
- cognition
- global functioning
- treatment adherence

Based on reference 4

A recommended monitoring schedule for lithium in a patient not taking other drugs is outlined in the Box.⁴ Drug interactions are more likely to affect patients as they get older because of declining renal function and the accumulation of medical comorbidities. Close monitoring and dose adjustments are therefore often needed as patients get older.

In patients taking concomitant drugs, extra care should be taken because of the risk of drug interactions. Lithium concentrations should be closely monitored around the time of medication changes – at least just before and when the drugs have reached steady states. Lithium's half-life is about 24 hours, so a steady state is usually achieved after 5–7 days. A complete list of lithium drug interactions can be found at MIMS Online or Drugs.com.

Regular monitoring is required until a therapeutic concentration of lithium is reached and maintained, and any time that the patient presents with symptoms of lithium toxicity.⁷ Conditions leading to haemodynamic and volume changes such as dehydration, febrile illness, gastrointestinal loss, drug interactions, perioperative management and surgery can affect lithium serum concentrations and levels should be rechecked in these circumstances.

Prescribers should contact the treating psychiatrist or consult a medicines information pharmacist if they are unsure how to manage a patient. Having up-to-date serum lithium concentrations at hand will assist.

Adverse effects of lithium

Regular long-term monitoring of lithium concentrations is essential to avoid both acute and chronic toxicity. Physical examinations and laboratory investigations should be performed at baseline and regular intervals after that (see Box).

Common acute adverse effects include tremor, polydipsia, polyuria, dysgeusia, nausea and diarrhoea (see Table). Prescribers can reassure patients that these adverse effects are usually transient after starting treatment. They are often dependent on the serum concentration of lithium and frequently subside within days or weeks. Nephrogenic diabetes insipidus (polyuria and polydipsia) is a common adverse effect of lithium.

Chronic adverse effects include subjective cognitive effects, thyroid and parathyroid dysfunction, and renal dysfunction (see Table). Some patients may report more mild neurocognitive effects such as 'brain fog', 'emotional greying', 'slowing', 'shakiness', anomia, and 'reduced creativity'. The higher the lithium concentration, the greater the risk of toxic presentations. In the long term, or with higher blood concentrations or repeated acute fluctuations, lithium leads to end-stage renal failure in 1% of patients (over 15 years treatment).⁸ However, it should be noted that most patients do not experience renal adverse effects.

Table Major adverse effects of lithium therapy

Toxicity	Adverse effect	Action
Acute	Any acute adverse effect or presentation	Measure lithium concentration
	Headache, fatigue	Consider stopping lithium
	Thirst, taste	Review medication
	Arrhythmias	Hospitalisation
	Nausea, vomiting, diarrhoea, polyuria	Review hydration and consider haemodialysis
	Tremor	Monitoring and review medication
Chronic	Cognitive effects, ataxia, agitation, confusion, sluggishness	Monitor changes, optimise lithium concentrations, neurological referral
	Thyroid or parathyroid dysfunction	Monitor changes, optimise lithium concentrations, endocrinology referral
	Renal dysfunction	Monitor changes, optimise lithium concentrations, nephrology referral

Common drug–drug interactions with lithium

The most common and noteworthy drug–drug interactions with lithium are pharmacokinetic in nature. The lithium ion is extensively absorbed in the gastrointestinal tract. The main determinant of serum concentrations is renal excretion, therefore the main drug interactions occur when co-administered drugs alter renal function, specifically modifying glomerular filtration and tubular reabsorption.

The most commonly prescribed drugs that have the potential to interact with lithium are ACE inhibitors, angiotensin II receptor antagonists (sartans), diuretics, and non-steroidal anti-inflammatory drugs (NSAIDs). Combinations of these are frequently used, so prescribers should be aware of their additive effects for a patient taking lithium.

ACE inhibitors and angiotensin II receptor antagonists

Several case reports and hospital admission studies have shown that ACE inhibitors and angiotensin II receptor antagonists can increase lithium serum concentrations and increase the chance of toxicity. Closer monitoring of lithium concentrations is needed when people start either of these drugs and the lithium dose will probably need to be reduced until a stable therapeutic concentration has been achieved. Closer monitoring is also required when these drugs are stopped.

Diuretics

When any diuretic is used, lithium concentrations must be carefully monitored. Thiazide and thiazide-like diuretics increase sodium reabsorption which decreases the clearance of lithium and significantly elevates lithium concentrations in serum. This is enough to fall out of the therapeutic range in many cases. As a rule of thumb, many prescribers halve the lithium dose then up- or down-titrate the dose with monitoring. Other prescribers avoid thiazide diuretics altogether. Amiloride is recommended as a diuretic because it blocks entry of lithium through the epithelial sodium channel in the collecting duct. This reduces lithium accumulation and may improve kidney function in patients on long-term treatment.⁹

Other diuretics such as the osmotic methylxanthine (e.g. theophylline) and loop (e.g. furosemide (frusemide)) and potassium-sparing (e.g. spironolactone) diuretics may also alter lithium concentrations.

Non-steroidal anti-inflammatory drugs

Patients on lithium therapy should be advised to avoid NSAIDs. Regular use is more problematic than episodic use. NSAIDs differentially alter lithium concentrations by multiple mechanisms, and one of these is to reduce prostaglandin E2 by inhibiting cyclo-oxygenase. This reduces vasodilation of the afferent arteriole which decreases blood flow to the glomerulus. This decreases glomerular filtration and consequently lithium excretion. If NSAIDs are indicated, they should be used under medical guidance with closer monitoring of lithium concentrations. Lower lithium doses may be required.

Other drugs

Acetazolamide for intraocular pressure, glaucoma and epilepsy has been shown to significantly increase lithium clearance.

Conclusion

Lithium has an important role in the treatment of mood disorders. Prescribers need to be mindful of its potential drug interactions and the impact they can have on patients. Improved knowledge of and confidence with monitoring will contribute to better patient outcomes. ◀

Gin Malhi has received grant or research support from the National Health and Medical Research Council, Australian Rotary Health, NSW Health, Ramsay Health, American Foundation for Suicide Prevention, Ramsay Research and Teaching Fund, Elsevier, AstraZeneca and Servier; has been a speaker for AstraZeneca, Janssen-Cilag, Lundbeck, Otsuka and Servier; and has been a consultant for AstraZeneca, Janssen Cilag, Lundbeck, Otsuka and Servier.

Michael Berk is supported by a National Health and Medical Research Council Senior Principal Research Fellowship (1059660 and APP1156072).

REFERENCES

- Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. *Lancet* 2016;387:1561-72. [https://doi.org/10.1016/S0140-6736\(15\)00241-X](https://doi.org/10.1016/S0140-6736(15)00241-X)
- Vieta E, Berk M, Schulze TG, Carvalho AF, Suppes T, Calabrese JR, et al. Bipolar disorders. *Nat Rev Dis Primers* 2018;4:18008. <https://doi.org/10.1038/nrdp.2018.8>
- Ng F, Mammen OK, Wilting I, Sachs GS, Ferrier IN, Cassidy F, et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. *Bipolar Disord* 2009;11:559-95. <https://doi.org/10.1111/j.1399-5618.2009.00737.x>
- Malhi GS, Gershon S, Outhred T. Lithiumeter: Version 2.0. *Bipolar Disord* 2016;18:631-41. <https://doi.org/10.1111/bdi.12455>
- Grof P, Duffy A, Cavazzoni P, Grof E, Garnham J, MacDougall M, et al. Is response to prophylactic lithium a familial trait? *J Clin Psychiatry* 2002;63:942-7. <https://doi.org/10.4088/JCP.v63n1013>
- Malhi, GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. *Aust N Z J Psychiatry* 2015;49:1087-206. <http://doi.org/10.1177/0004867415617657>
- Ott M, Stegmayr B, Salander Renberg E, Werneke U. Lithium intoxication: Incidence, clinical course and renal function - a population-based retrospective cohort study. *J Psychopharmacol* 2016;30:1008-19. <https://doi.org/10.1177/0269881116652577>
- Azab AN, Shnaider A, Osher Y, Wang D, Bersudsky Y, Belmaker RH. Lithium nephrotoxicity. *Int J Bipolar Disord* 2015;3:13. <https://doi.org/10.1186/s40345-015-0028-y>
- Battle DC, von Rottte AB, Gaviria M, Grupp M. Amelioration of polyuria by amiloride in patients receiving long-term lithium therapy. *N Engl J Med* 1985;312:408-14. <https://doi.org/10.1056/NEJM198502143120705>

New drugs

Aust Prescr 2020;43:94–5
<https://doi.org/10.18773/austprescr.2020.026>
First published
24 April 2020

Abemaciclib

Approved indication: breast cancer

Verzenio (Eli Lilly)

50 mg, 100 mg and 150 mg tablets

Like palbociclib and ribociclib, abemaciclib is a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4 and 6. These kinases are involved in cell cycle progression and are often overexpressed in hormone receptor positive (HR+) breast cancers. Blocking them leads to cell cycle arrest, senescence and apoptosis.

Abemaciclib is specifically indicated for HR+/human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant. It can be given as initial endocrine-based therapy, or after previous endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone-releasing hormone agonist.

Abemaciclib has been assessed in three clinical trials of women with HR+/HER2- advanced breast cancer: MONARCH 1, 2 and 3 (see Table). MONARCH 1 was a single-arm, phase II trial in women who had failed two endocrine therapies and had already had 1–2 chemotherapy regimens. Women received abemaciclib monotherapy 200 mg twice daily.

At 12 months, the objective response rate was 19.7% (all partial responses), median progression-free survival was six months and the median overall survival was 17.7 months (see Table).¹

The MONARCH 2 trial was a double-blind, phase III trial in 669 women who had progressed during endocrine therapy but had not received chemotherapy. They were randomised to receive fulvestrant in combination with abemaciclib (150 mg twice daily) or placebo. Median progression-free survival was significantly longer with abemaciclib than with placebo (16.4 vs 9.3 months)² as was median overall survival (46.7 vs 37.3 months).³ The corresponding objective response rates were 35.2% and 16.1%.

MONARCH 3 was another double-blind, phase III trial. The 493 women enrolled had not received previous systemic therapy and most had metastatic disease at baseline. They were randomised to an aromatase inhibitor (anastrozole or letrozole) plus abemaciclib (150 mg twice daily) or placebo. Median progression-free survival was significantly longer with abemaciclib than with placebo (28.2 vs 14.7 months). The corresponding objective response rates were 48.2% versus 34.5%.⁴

The most common adverse effects with abemaciclib include diarrhoea (84.6% of patients), neutropenia (45.1%), nausea (43.5%), infections (43.6%),



Some of the views expressed in the following notes on newly approved products should be regarded as preliminary, as there may be limited published data at the time of publication, and little experience in Australia of their safety or efficacy. However, the Editorial Executive Committee believes that comments made in good faith at an early stage may still be of value. Before new drugs are prescribed, the Committee believes it is important that more detailed information is obtained from the manufacturer's approved product information, a drug information centre or some other appropriate source.

Table Efficacy of abemaciclib in HR+/HER2- advanced breast cancer

Trial	Daily treatment	No. of patients	ORR	Median progression-free survival	Median overall survival
MONARCH 1 ¹	abemaciclib monotherapy	132	19.7%	6 months	17.7 months
MONARCH 2 ^{2,3}	abemaciclib + fulvestrant	446	35.2%	16.4 months	46.7 months
	placebo + fulvestrant	223	16.1%	9.3 months	37.3 months
MONARCH 3 ⁴	abemaciclib + aromatase inhibitor*	326	48.2%	28.2 months	–
	placebo + aromatase inhibitor*	162	34.5%	14.7 months	–

* anastrozole or letrozole

HR+ hormone receptor positive

HER2- human epidermal growth factor receptor 2 negative

ORR objective response rate estimated as the total number of complete and partial responses divided by the number of patients

fatigue (40.5%), anaemia (30.1%) and vomiting (27.7%). Hair loss occurred in 20.7% women. Hepatotoxicity and venous thromboembolism were also reported in the trials.

Diarrhoea was serious in 11.7% of cases. Onset was 6–8 days after the start of treatment and severe cases lasted for about a week. If this occurs, the abemaciclib dose should be interrupted until symptoms resolve. Fluids and an antidiarrhoeal medicine such as loperamide are recommended.

Neutropenia was serious in 28% of patients who were taking abemaciclib and fulvestrant, and fatal cases have occurred. Onset was a month after the start of treatment. Blood counts should therefore be measured at baseline and then monitored regularly.

Dose reduction or interruption may be required with serious adverse effects such as diarrhoea and haematologic and liver toxicities. As with other drugs in this class, abemaciclib can cause interstitial lung disease. In serious cases, the drug should be permanently discontinued.

The recommended starting dose of abemaciclib is 150 mg twice daily in combination with endocrine therapy. As the drug is metabolised in the liver, the dose should be reduced to one tablet a day in those with severe liver impairment. After oral administration, peak plasma concentrations are reached within eight hours and repeated dosing results in steady-state concentrations after five days. Abemaciclib's elimination half-life is 25 hours and most of the dose is excreted in the faeces.

Abemaciclib is metabolised by cytochrome P450 (CYP) 3A so concurrent use of strong inhibitors (e.g. clarithromycin, itraconazole, ketoconazole) and inducers (e.g. carbamazepine, rifampicin, St John's wort) is best avoided. If co-administration of a strong inhibitor cannot be avoided, the abemaciclib dose should be reduced.

Abemaciclib prolongs progression-free survival when used in combination with fulvestrant or an aromatase inhibitor in women with advanced HR+/HER2- breast cancer. As with palbociclib and ribociclib, diarrhoea is very common and may limit treatment. Severe neutropenia does not seem to be as common with abemaciclib as it was with palbociclib.

T [manufacturer provided useful information](#)

REFERENCES

1. Dickler MN, Tolaney SM, Rugo HS, Cortés J, Diéras V, Patt D, et al. MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. *Clin Cancer Res* 2017;23:5218-24. <https://doi.org/10.1158/1078-0432.CCR-17-0754>
2. Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. *J Clin Oncol* 2017;35:2875-84. <https://doi.org/10.1200/JCO.2017.73.7585>
3. Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy – MONARCH 2: a randomized clinical trial. *JAMA Oncol* 2020;6:116-24. <https://doi.org/10.1001/jamaoncol.2019.4782>
4. Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. *J Clin Oncol* 2017;35:3638-46. <https://doi.org/10.1200/JCO.2017.75.6155>

The Transparency Score is explained in [New drugs: transparency, Vol 37 No 1, Aust Prescr 2014;37:27](#).

At the time the comment was prepared, information about this drug was available on the websites of the [Food and Drug Administration](#) in the USA, and the [European Medicines Agency](#).

Aust Prescr 2020;43:96–7
<https://doi.org/10.18773/austprescr.2020.027>
 First published
 24 April 2020

Acalabrutinib

Approved indication: mantle cell lymphoma, chronic lymphocytic leukaemia

**Calquence (AstraZeneca)
 100 mg capsules**

Acalabrutinib is an oral small-molecule drug similar to ibrutinib for B-cell malignancies. It works by binding to Bruton's tyrosine kinase and blocking signalling through the B-cell receptor and cytokine receptor pathways. This inhibits the proliferation of B cells.

This drug is indicated for mantle cell lymphoma and chronic lymphocytic leukaemia. (The approval for mantle cell lymphoma is provisional pending more trials.) The recommended dose is one capsule twice a day as monotherapy. For chronic lymphocytic leukaemia acalabrutinib can also be given in combination with obinutuzumab.

Mantle cell lymphoma

The efficacy of acalabrutinib 100 mg twice daily was investigated in an open-label, single-arm, phase II trial of 124 patients with relapsed or refractory mantle cell lymphoma. All participants had been previously treated and some had had a stem cell transplant. After a median of 15.2 months, 81% of patients had responded to treatment and 40% had a complete

response. The estimated overall survival rate at 12 months was 87%.¹

Chronic lymphocytic leukaemia

The approval of acalabrutinib for chronic lymphocytic leukaemia appears to be based on two phase III, open-label trials that have not yet been published in full. One of the trials enrolled people with previously untreated disease. They were randomised to acalabrutinib plus obintuzumab, acalabrutinib monotherapy or chlorambucil plus obinutuzumab. After a median follow-up of 28.3 months, there was less progressive disease and fewer deaths in the acalabrutinib groups than in the comparator group (see Table).

The other trial assessed efficacy in patients with relapsed or refractory disease. They received acalabrutinib monotherapy or the investigator's choice of idelalisib plus rituximab or bendamustine plus rituximab. After a median follow-up of 16.1 months, there was less disease progression with acalabrutinib than with the comparator, but the number of deaths were similar (see Table).

Pharmacology and drug interactions

Following oral administration, peak plasma concentrations of acalabrutinib and its active metabolite (ACP-5862) are reached within an hour. The median terminal half-life of the active metabolite is 6.9 hours and most of the dose is excreted in the

Table Efficacy of acalabrutinib in chronic lymphocytic leukaemia*

Patients with previously untreated disease			
	Acalabrutinib plus obintuzumab (179 patients)	Acalabrutinib monotherapy (179 patients)	Chlorambucil plus obinutuzumab (177 patients)
Progressive disease	5%	11.2%	46.3%
Death	2.8%	3.4%	6.2%
Estimated progression-free survival at 24 months	92.7%	87.3%	46.7%
ORR	93.9%	85.5%	78.5%
Patients with relapsed or refractory disease			
	Acalabrutinib monotherapy (155 patients)	Investigator's choice† (155 patients)	
Progressive disease	12.3%	38.1%	
Death	5.2%	5.8%	
Estimated progression-free survival at 15 months	82.6%	54.9%	
ORR	81.3%	75.5%	

* based on data in the product information

† idelalisib plus rituximab or bendamustine plus rituximab

ORR objective response rate estimated as the number of complete and partial responses divided by the total number of patients

faeces. The drug is mainly metabolised by cytochrome P450 (CYP) 3A enzymes so co-administration with strong CYP3A inhibitors (e.g. itraconazole) and inducers (e.g. rifampicin) increase the risk of toxicity or reduce the efficacy of acalabrutinib and should be avoided. Dose adjustment of acalabrutinib may be needed with moderate CYP3A inhibitors such as erythromycin. Drugs that increase the pH of the stomach can decrease acalabrutinib concentrations. Proton pump inhibitors should be avoided and H₂-receptor antagonists should only be used two hours after the acalabrutinib dose. Antacids should be dosed separately by at least two hours.

Adverse events

The most common adverse effects with acalabrutinib in the trials included headache (22–40% of patients), diarrhoea (18–39%), fatigue (10–28%), muscle pain (15–37%) and bruising (12–34%). Cytopenias were very common and included neutropenia (21%), anaemia (10%) and thrombocytopenia (7%). Serious bleeding occurred in 3.6% of patients receiving acalabrutinib and one patient died. Concomitant use of anti-thrombotic drugs should therefore be avoided with acalabrutinib.

Atrial fibrillation was a concerning adverse effect with the related drug ibrutinib. In the combined safety cohort of the acalabrutinib trials, 1% of patients had grade 3 atrial fibrillation and 3% had milder events. ECG is recommended if patients develop palpitations, dizziness, syncope, chest pain or dyspnoea.

Infections were frequently reported in the chronic lymphocytic leukaemia trials and affected 57–69% of patients receiving acalabrutinib. Pneumonia was the most commonly reported serious infection. Hepatitis B reactivation and progressive multifocal leukoencephalopathy have also occurred with acalabrutinib.

Conclusion

Acalabrutinib seems to benefit patients with mantle cell lymphoma and chronic lymphocytic leukaemia. For both indications, over 80% of patients in the trials responded to treatment. In chronic lymphocytic leukaemia, acalabrutinib was associated with longer progression-free survival compared to the comparator treatments. It is not yet clear if the drug improves overall survival. Adverse effects are common and sometimes serious so may limit treatment.

T manufacturer provided the AusPAR and the product information

REFERENCE

1. Wang M, Rule S, Zinzani PL, Goy A, Casanovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. *Lancet* 2018;391:659-67. [https://doi.org/10.1016/S0140-6736\(17\)33108-2](https://doi.org/10.1016/S0140-6736(17)33108-2)

The Transparency Score is explained in [New drugs: transparency, Vol 37 No 1, Aust Prescr 2014;37:27.](#)

At the time the comment was prepared, information about this drug was available on the websites of the [Food and Drug Administration](#) in the USA, and the [European Medicines Agency](#) and the [Therapeutic Goods Administration](#).

Ceftazidime/avibactam

Aust Prescr 2020;43:98–9
<https://doi.org/10.18773/austprescr.2020.028>

First published
24 April 2020

Approved indication: specified infections

Zavicefta (Pfizer)

vials containing 2000 mg/500 mg as powder for reconstitution

Bacterial resistance to cephalosporins is increasing. The bacteria produce beta-lactamase enzymes which reduce the efficacy of beta-lactam antibiotics, such as penicillins and cephalosporins. Combining the antibiotic with an inhibitor of beta-lactamase can help to overcome bacterial resistance. One example is the combination of amoxicillin and clavulanic acid. Similarly, ceftazidime pentahydrate has been combined with the beta-lactamase inhibitor avibactam sodium. This combination aims to overcome resistance in serious infections caused by organisms such as the Enterobacteriaceae and *Pseudomonas aeruginosa*.

The formulation of ceftazidime and avibactam has to be reconstituted with water and then added to an infusion bag. This solution is then infused intravenously over two hours. The infusion is repeated every eight hours with the recommended duration of treatment being guided by the type of infection.

The activity of the combination is correlated with the concentration of free drug. The penetration of ceftazidime across the blood–brain barrier is poor, but this increases if the meninges are inflamed. Ceftazidime can cross the placenta and is excreted in breast milk. There is some evidence of reproductive toxicity with avibactam in animal studies.

The combination has a half-life of approximately two hours. Both components are excreted unchanged into the urine. Dose adjustment is required in patients with moderate or severe renal impairment.

An open-label trial assessed the efficacy of the combination of ceftazidime with avibactam in treating infections caused by Gram-negative bacteria resistant to ceftazidime. The 333 patients in the study mainly had complicated infections of the urinary tract, such as pyelonephritis, but some had complicated intra-abdominal infections. They received either the combination or the best available therapy, for example a carbapenem such as meropenem. When assessed 7–10 days after the final infusion there was a clinical cure in 91% of each treatment group.¹

The double-blind RECLAIM trials compared ceftazidime/avibactam plus metronidazole to meropenem. RECLAIM 1 and 2 randomised 1066 patients with complicated intra-abdominal infections

requiring surgical intervention or percutaneous drainage. It was possible to isolate the pathogens in 823 patients. In 111 patients there was a ceftazidime-resistant aerobic Gram-negative organism. When the 823 patients were assessed 28–35 days after randomisation there had been a cure in 81.6% of those treated with the combination and metronidazole compared with 85.1% of the meropenem group. The outcomes were similar in the patients with ceftazidime-resistant Gram-negative infections – 83% (39/47) versus 85.9% (55/64).²

A similar trial, RECLAIM 3, involved 441 patients in Asia. When they were evaluated 28–35 days after randomisation the proportion with a clinical cure was almost the same for the combination plus metronidazole as it was for meropenem (93.8% vs 94%). In 239 cases, the cause of the complicated intra-abdominal infection was identified as one of the Enterobacteriaceae. These patients were analysed in an intention-to-treat group. The clinical cure rate in this group was 83.2% with the combination plus metronidazole, and 88.8% with meropenem.³

The combination was also compared with meropenem in a study of nosocomial pneumonia. The double-blind REPROVE trial involved 817 patients including 246 with ventilator-associated pneumonia. Gram-negative bacteria, such as *Klebsiella pneumoniae* and *Pseudomonas aeruginosa*, were identified in 355 patients. In the patients who were clinically evaluable 21–25 days after randomisation there was a clinical cure in 77.4% (199/257) of the combination group and 78.1% (211/270) of the meropenem group. For an intention-to-treat population the corresponding results were 68.8% (245/356) and 73% (270/370). There were 38 deaths (9%) in the patients treated with ceftazidime/avibactam and 30 (7%) in the meropenem group.⁴

Ceftazidime/avibactam has been compared with doripenem, another carbapenem, in the treatment of complicated urinary tract infections, such as pyelonephritis. The two double-blind RECAPTURE trials randomised 1033 patients including 810 with identified bacteria. *Escherichia coli* was the most frequently isolated organism. The bacteria were resistant to ceftazidime in 19.6% of the patients. After five days of treatment, symptoms had resolved in 70.2% of the combination group and 66.2% of the doripenem group. At 21–25 days after randomisation infection had been eradicated in 77.4% of the patients treated with the combination and 71% of those infused with doripenem. The clinical cure rates were identical (89.3%) in the patients infected with ceftazidime-resistant bacteria.⁵

As ceftazidime has been available for many years its adverse effects such as hypersensitivity are well known. It is not yet clear what additional adverse effects the combination with avibactam may have. Based on analysis of 2024 patients who received ceftazidime/avibactam in clinical trials, adverse events were reported in 49.2%. Not considering deaths due to disease progression, 2% died with most deaths occurring in patients with pneumonia.⁴ Common adverse effects include nausea, vomiting and diarrhoea. Some cases of diarrhoea may be associated with *Clostridioides difficile*.

Adding avibactam extends the range of bacteria that can be treated with ceftazidime. As it is important to reserve antibiotics against resistant bacteria, the use of ceftazidime/avibactam should be limited to the conditions studied in the trials. The combination has therefore been approved for complicated urinary tract infections, hospital-acquired pneumonia, and complicated intra-abdominal infections in combination with metronidazole. Although the overall outcomes were statistically non-inferior to meropenem for intra-abdominal infections, there was a trend favouring meropenem in patients with moderate renal impairment.² Close monitoring of renal function will be needed. It is important to remember that the combination will have little activity against Gram-positive bacteria.

T [manufacturer provided the product information](#)

The Transparency Score is explained in [New drugs: transparency, Vol 37 No 1, Aust Prescr 2014;37:27](#).

At the time the comment was prepared, information about this drug was available on the websites of the [Food and Drug Administration](#) in the USA, and the [European Medicines Agency](#) and the [Therapeutic Goods Administration](#).

REFERENCES

1. Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and *Pseudomonas aeruginosa* complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. *Lancet Infect Dis* 2016;16:661-73. [https://doi.org/10.1016/S1473-3099\(16\)30004-4](https://doi.org/10.1016/S1473-3099(16)30004-4)
2. Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. *Clin Infect Dis* 2016;62:1380-9. <https://doi.org/10.1093/cid/ciw133>
3. Qin X, Tran BG, Kim MJ, Wang L, Nguyen DA, Chen Q, et al. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia. *Int J Antimicrob Agents* 2017;49:579-88. <https://doi.org/10.1016/j.ijantimicag.2017.01.010>
4. Torres A, Zhong N, Pachi J, Timsit JF, Kollef M, Chen Z, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. *Lancet Infect Dis* 2018;18:285-95. [https://doi.org/10.1016/S1473-3099\(17\)30747-8](https://doi.org/10.1016/S1473-3099(17)30747-8)
5. Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, et al. Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. *Clin Infect Dis* 2016;63:754-62. <https://doi.org/10.1093/cid/ciw378>

Isavuconazole

Aust Prescr 2020;43:100-101
<https://doi.org/10.18773/austprescr.2020.035>

Approved indication: invasive fungal infections

Cresemba (Pfizer)

100 mg capsules, vials containing 200 mg powder for injection

Isavuconazole, which comes in the form of a prodrug isavuconazonium sulfate, is a triazole antifungal indicated for adults with invasive aspergillosis. It is also approved for the rare condition of invasive mucormycosis when amphotericin B is not appropriate. Like other drugs in the class, it works by inhibiting the synthesis of ergosterol which is an essential part of the fungal cell membrane.

The approval of isavuconazole is based on two main clinical studies – the SECURE trial¹ and the VITAL trial.² The SECURE trial was a phase III non-inferiority study comparing isavuconazole with voriconazole. It enrolled patients with invasive fungal disease mainly caused by *Aspergillus* species (e.g. *A. fumigatus*, *A. flavus*, *A. niger* and *A. terreus*). Some patients had other fungi isolated including unidentified filamentous fungi. Over 80% of the patients had a haematological malignancy, 20% had had a stem cell transplant and 66% had neutropenia at baseline.

Patients randomised to isavuconazole (n=258) were started on the intravenous formulation (200 mg three times a day), then continued or switched to capsules (200 mg daily) on the third day. Patients assigned to voriconazole (n=258) were given the drug intravenously on days one and two (6 mg/kg twice daily then 4 mg/kg twice daily) and then continued (4 mg/kg intravenously twice daily) or switched to oral voriconazole (200 mg twice daily) on day three. After a median of 45 and 47 days of treatment, all-cause mortality rates for isavuconazole and voriconazole were similar – 19% versus 20%. The corresponding treatment response rates in patients with proven or probable invasive aspergillosis were 35% and 36%.¹

The VITAL trial was an open-label, single-arm study that enrolled 37 patients with proven or probable invasive mucormycosis. This included previously treated and treatment-naïve patients. Fungi identified at baseline included *Mucorales* moulds, *Mucor* species, *Rhizomucor* species, *Rhizopus oryzae* and *Lichteimia corymbifera*. Participants received the same isavuconazole dosing regimen as in the SECURE trial for a median of 84 days. By the end of the trial, 14% of the patients had a complete response to treatment. All-cause mortality was 43%.²

In a safety cohort of 403 patients, the most common adverse effects related to isavuconazole included

nausea (7.4% of patients), vomiting (5.5%), dyspnoea (3.2%), abdominal pain (2.7%), diarrhoea (2.7%), injection-site reactions (2.2%), headache (2%) and rash (1.7%).

Skin, eye and hepatobiliary disorders were less common with isavuconazole than with voriconazole. In the SECURE trial, elevated liver laboratory tests were reported in 17.1% of patients in the isavuconazole group and 24.3% in the voriconazole group. Liver function should be tested before and during treatment. Isavuconazole is not recommended in those with severe liver impairment.

As isavuconazole shortens the QTc interval, it is contraindicated in patients who have familial short QT syndrome.

Isavuconazole is a pregnancy category D drug and is not recommended during pregnancy. In animal studies, it was associated with dose-related increases in fetal rib abnormalities. It is also not recommended during lactation as there was evidence of its excretion in the milk of lactating rats.

Isavuconazole has many potential drug interactions so it is prudent to consult the product information before prescribing in patients taking other medicines. Isavuconazole should not be given with concomitant ketoconazole, high-dose ritonavir (>200 mg/12 hourly) or drugs that strongly induce cytochrome P450 (CYP) 3A4/5 (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin, St John's wort). It is also contraindicated with moderate CYP3A4/5 inducers (e.g. efavirenz, nafcillin, etravirine). Concomitant use with mild inducers should also be avoided.

Isavuconazole may increase exposure to drugs that are metabolised by CYP3A4/5 such as tacrolimus, sirolimus and ciclosporin. Therapeutic monitoring and dose adjustment of these drugs may be needed. Dose adjustment may be needed for substrates of P-glycoprotein as toxicity may be a concern, particularly with drugs that have a narrow therapeutic index such as digoxin, colchicine and dabigatran.

This antifungal comes in the form of a water-soluble prodrug, isavuconazonium sulfate, which can be given intravenously or orally. Following administration, it is rapidly hydrolysed to isavuconazole by esterases in plasma. Maximum concentrations of this active metabolite are reached within 2–3 hours of oral administration. Food does not affect absorption. It is mainly metabolised by CYP3A4/5 and uridine diphosphate-glucuronosyltransferases. The product information recommends that no dose adjustment is required in renal or hepatic impairment. The drug has not been studied in severe hepatic impairment.

Isavuconazole appears to be non-inferior to voriconazole for patients with invasive aspergillosis.

It was also of benefit in some patients with invasive mucormycosis. However, the trial was small with no comparator and the activity of isavuconazole on individual fungi was difficult to assess.² It is not known how isavuconazole will compare to other azole antifungals. The safety and efficacy of isavuconazole in children has not yet been established.

T manufacturer provided the AusPAR

REFERENCES

1. Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by *Aspergillus* and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. *Lancet* 2016;387:760-9. [https://doi.org/10.1016/S0140-6736\(15\)01159-9](https://doi.org/10.1016/S0140-6736(15)01159-9)
2. Marty FM, Ostrosky-Zeichner L, Cornely OA, Mullane KM, Perfect JR, Thompson GR 3rd, et al.; VITAL and FungiScope Mucormycosis Investigators. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. *Lancet Infect Dis* 2016;16:828-37. [https://doi.org/10.1016/S1473-3099\(16\)00071-2](https://doi.org/10.1016/S1473-3099(16)00071-2)

The Transparency Score is explained in [New drugs: transparency, Vol 37 No 1, Aust Prescr 2014;37:27.](#)

At the time the comment was prepared, information about this drug was available on the websites of the [Food and Drug Administration in the USA](#), and the [European Medicines Agency](#) and the [Therapeutic Goods Administration](#).

Stiripentol

Aust Prescr 2020;43:102
<https://doi.org/10.18773/austprescr.2020.029>

First published
24 April 2020

Approved indication: Dravet syndrome

Diacomit (Emerge Health)

250 mg and 500 mg capsules

250 mg and 500 mg powder for oral suspension

Dravet syndrome is a severe myoclonic epilepsy in infancy. It usually emerges in the first year of life. The seizures are difficult to control and the infants develop intellectual disability. Stiripentol has been approved as an adjunctive treatment for infants with generalised tonic-clonic and clonic seizures which are not controlled by valproate and a benzodiazepine.

Stiripentol is an aromatic alcohol which is unrelated to the structure of other antiepileptic drugs. It increases activity in the GABAergic system, but it also interacts with anticonvulsant drugs. Stiripentol inhibits cytochrome P450 (CYP) 1A2, 2C8, 2C9, 2C19, 2D6 and 3A4. It therefore increases the plasma concentrations of antiepileptic drugs including carbamazepine, clobazam, phenytoin and valproate. There are many other potential pharmacokinetic interactions, including with benzodiazepines.

Stiripentol is well absorbed, but there is extensive first-pass metabolism. While they are not the main method of metabolism, CYP1A2, 2C19 and 3A4 are involved. The clearance of stiripentol decreases after several doses probably because it inhibits its own metabolism. A steady state is established after 2–5 days. Most of the metabolites are excreted in the urine. The elimination half-life is 4.5–13 hours.

As Dravet syndrome is rare, the trials of stiripentol have involved small numbers of patients. The two main trials of efficacy involved a total of 64 patients. In these double-blind trials stiripentol was added to optimised treatment with clobazam and valproate. The recommended daily dose was 50 mg/kg. An infant was considered to have responded to treatment if there was at least a 50% decrease in the frequency of seizures.^{1,2}

One of these trials was in France. It randomised 21 children (average age 9.4 years) to stiripentol and 20 to placebo. In the first two months of the trial 15 (71%) in the stiripentol group responded compared with one (5%) in the placebo group. Nine of the children taking stiripentol became seizure free.¹

The other trial was in Italy and involved 23 children with an average age of 9.1 years. After two months, eight children responded to stiripentol (66.7%). Only one (9.1%) in the placebo group responded. Three of the children taking stiripentol became free of seizures.²

During the trials there were more adverse events in the children taking stiripentol, compared to placebo. More frequent effects included drowsiness, agitation, irritability, hypotonia, nausea and vomiting. There was also loss of appetite and weight loss. Elevation of gamma-glutamyltransferase has been reported so liver function should be checked every six months, as should a full blood count because of the risk of neutropenia.

While it is difficult to know if the effect is due to its interaction with clobazam and valproate, stiripentol reduced seizures more than a placebo did. When starting stiripentol it should be given two or three times a day with the dose being gradually increased. The doses of clobazam and valproate may need to be reduced if adverse effects emerge. Long-term efficacy and safety data are limited. For example, does the weight loss, which was seen in 24% of the children taking stiripentol, have a long-term effect on growth?

T [manufacturer provided useful information](#)

REFERENCES

1. Chiron C, Marchand MC, Tran A, Rey E, d'Athis P, Vincent J, et al; STICLO study group. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. *Lancet* 2000;356:1638-42. [https://doi.org/10.1016/S0140-6736\(00\)03157-3](https://doi.org/10.1016/S0140-6736(00)03157-3)
2. Guerrini R, Tonnelier S, d'Athis P, Rey E, Vincent J, Pons G, et al; STICLO Italian study group. Stiripentol in severe myoclonic epilepsy in infancy (SMEI): a placebo-controlled Italian trial. Poster session 496. *Epilepsia* 2002;43 Suppl 8:155. <https://doi.org/10.1111/j.1528-1167.2002.tb06320.x>

The Transparency Score is explained in [New drugs: transparency, Vol 37 No 1, Aust Prescr 2014;37:27.](#)

At the time the comment was prepared, information about this drug was available on the websites of the [Food and Drug Administration](#) in the USA, and the [European Medicines Agency](#) and the [Therapeutic Goods Administration](#).

Correction

Faecal microbiota transplantation: indications, evidence and safety [Correction]

Aust Prescr 2020;43:103

<https://doi.org/10.18773/austprescr.2020.032>

The article on faecal microbiota transplantation (*Aust Prescr* 2020;43:36-8) has been corrected. [View corrected article.](#)

The conflict of interest statement was inadvertently omitted during the production process. It should have read:

Robert V Bryant has received speaker fees, grants and research support from AbbVie, Ferring, Janssen, Shire, Takeda and Emerge Health. These fees were paid to his employer to support research. He is also a board member and shareholder of BiomeBank.

Samuel P Costello has received speaker fees, grants and research support from Ferring, Janssen, Shire and Microbiotica. He is also a board member and shareholder of BiomeBank.

EDITORIAL OFFICE

For general correspondence such as Letters to the Editor, contact the Editor.

Postal The Editor
Australian Prescriber
GPO Box 266
Canberra, ACT 2600

Telephone +61 2 8217 8700

Email info@australianprescriber.com

Website nps.org.au/australian-prescriber

Twitter @AustPrescriber

SUBSCRIPTIONS

Australian Prescriber is published every two months online. All content is accessible free of charge in full text at nps.org.au/australian-prescriber. New drugs are published between issues as they become available.

An email alert can be sent to you when *Australian Prescriber* publishes new material. Subscribe or update your details at nps.org.au/australian-prescriber

For free copies of the Anaphylaxis wallchart and Switching-antidepressants poster, order online at www.nps.org.au/order#for-health-professionals

© 2020 NPS MedicineWise
ABN 61 082 034 393

NPS MedicineWise Disclaimer

Reasonable care is taken to provide accurate information at the time of creation. This information is not intended as a substitute for medical advice and should not be exclusively relied on to manage or diagnose a medical condition. NPS MedicineWise disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information.

EDITORIAL EXECUTIVE COMMITTEE

Chair

D Roberts – Clinical pharmacologist

Medical editor

JS Dowden

Deputy editor

FG Mackinnon

Members

L Ahmad – Geriatrician

I Coombes – Pharmacist

C Galletly – Psychiatrist

M Ryall – General physician/geriatrician

R Sutherland – General practitioner

SECRETARIAT AND PRODUCTION

Production manager

G Hickey

Editorial assistant

C Graham

Office administrator

J Dixon

ADVISORY EDITORIAL PANEL

Australasian Chapter of Addiction Medicine M McDonough
Australasian Chapter of Sexual Health Medicine K Lagios
Australasian College for Emergency Medicine J Holmes
Australasian College of Dermatologists ID McCrossin
Australasian College of Tropical Medicine K Winkel
Australasian Faculty of Occupational and Environmental Medicine E Thompson
Australasian Faculty of Rehabilitation Medicine G Bashford
Australasian Society for HIV Medicine J McMahon
Australasian Society for Infectious Diseases A Watson
Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists J Martin
Australasian Society of Clinical Immunology and Allergy C Katelaris
Australian and New Zealand Association of Neurologists F Vajda
Australian and New Zealand College of Anaesthetists K Brandis
Australian and New Zealand Society for Geriatric Medicine S Johns
Australian and New Zealand Society of Blood Transfusion J Isbister
Australian and New Zealand Society of Nephrology P Snelling
Australian and New Zealand Society of Palliative Medicine F Formby
Australian Birth Defects Society D Kennedy
Australian College of Nurse Practitioners J O'Connell
Australian College of Rural and Remote Medicine A Iannuzzi
Australian Dental Association J Matthews
Australian Medical Association J Gullotta
Australian Pharmaceutical Medical and Scientific Professionals Association K Hargreaves
Australian Rheumatology Association J Bertouch
Australian Society of Otolaryngology Head and Neck Surgery EP Chapman
Cardiac Society of Australia and New Zealand JHN Bett
Consumers Health Forum of Australia M Metherell
Endocrine Society of Australia RL Prince
Gastroenterological Society of Australia P Desmond
Haematology Society of Australia and New Zealand F Firkin
High Blood Pressure Research Council of Australia G Gabb
Internal Medicine Society of Australia and New Zealand M Kennedy
Joint Health Command, Australian Defence Force RG Beran
Medical Oncology Group of Australia SJ Clarke
National Heart Foundation of Australia G Jennings

Pharmaceutical Society of Australia W Plunkett
Royal Australasian College of Dental Surgeons PJ Sambrook
Royal Australasian College of Medical Administrators A Robertson
Royal Australasian College of Physicians N Buckley (adult division), J Ziegler (paediatric division)
Royal Australasian College of Surgeons M Westcott
Royal Australian and New Zealand College of Obstetricians and Gynaecologists M Hickey
Royal Australian and New Zealand College of Ophthalmologists M Steiner
Royal Australian and New Zealand College of Psychiatrists F Wilson
Royal Australian and New Zealand College of Radiologists P Carr
Royal Australian College of General Practitioners J Smith
Royal College of Pathologists of Australasia JM Potter
Society of Hospital Pharmacists of Australia C Alderman
Thoracic Society of Australia and New Zealand P Wark
Urological Society of Australia and New Zealand R Millard

AUSTRALIAN PRESCRIBER IS INDEXED AND ARCHIVED BY

- Academic Search Complete
- Academic Search Research and Development
- Australian Public Affairs Information Service - Health
- EMBASE/Excerpta Medica
- Emerging Sources Citation Index
- PubMed Central

The views expressed in this journal are not necessarily those of the Editorial Executive Committee or the Advisory Editorial Panel.

Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the Copyright Act 1968, or for purposes connected with teaching, material in this publication may not be reproduced without prior written permission from the publisher.

